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Chapter 1: Introduction and Scope of the Dissertation 
DNA Topology 
Every living organism on this planet has its genetic information coded in long strands of 
deoxyribonucleic acids (DNA)[1], which have an alphabet of four bases that pair in 
predetermined ways: adenine (A) pairs with thymine (T) and cytosine (C) pairs with guanine 
(G)[2, 3]. The bases on one strand of DNA form hydrogen bonds with their complementary bases 
on the other strand, thus forming the rungs of a ladder whose backbone is made up of a repeating 
pattern of a sugar (deoxyribose) and a phosphate group that are joined together through a 
phosphodiester bond[2]. The way that the bases pair and stack on top of one another, however, 
introduces a twist into the structure, such that the flat ladder is converted into a double-stranded 
helix[2]. This plectonemic coiling gives rise to an assortment of topological relationships and 
problems[4-8]. As a result, although the information contained in DNA is represented by its 
sequential array of bases, access to it is controlled by the three-dimensional structure of the 
double helix[4-8]. Different cellular processes – such as DNA replication, recombination, and 
transcription – require the opening of DNA[4, 5, 7, 9-11], but this creates torsional stress both 
ahead and behind the bubble of open genetic material[8]. 
James Watson and Francis Crick, Nobel Prize winners for correctly inferring the structure of 
DNA, followed up their seminal paper[2] with another publication that explored these very 
issues[3]. How, they wondered, do cells access the information within the stable structure of the 
double helix “without everything getting tangled”[3]? 
Globally, cells maintain their DNA in an underwound state, which facilitates its opening during 
necessary cell processes such as DNA replication[10, 12]. Because the number of turns of the 
double helix remains invariant (so long as the ends of DNA are not allowed to swivel, which can 
be considered to be the case in all cells[8]), as the replication (or other DNA tracking) machinery 
melts the DNA, it accumulates positive supercoils (associated with overwinding of the double 
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helix) ahead of replication forks and negative supercoils (associated with underwinding) behind 
the fork[8, 10, 12-14]. The problem with this situation becomes evident when we envision what 
happens if we were to grab each of two intertwined strings and pull from the middle: as we open 
the middle, we tighten the coils around the ends. When the strings are long enough, the tightness 
in the coils at each end of the open “bubble” is so strong that we cannot pull the strings apart 
anymore. This is exactly what happens with DNA; without a means of dealing with this torsional 
stress, cells cannot carry out processes that require the helix to be opened. 
Another topological problem associated with DNA during replication is catenation. The nature 
of semiconservative DNA replication[15-17]means that the generated products are catenated 
daughter chromosomes that must be separated (decatenated) for proper segregation into 
daughter cells during mitosis[12, 18-21]. 
These topological problems are exacerbated by the fact that DNA is a large molecule that be 
compacted by thousands of fold, which often results in tangling. The (haploid) human genome 
contains 3 billion base pairs and is approximately 1 m long and 2 nm in diameter, but the average 
human nucleus is only about 10 microns (µm) in diameter. That is roughly equivalent to taking a 
rope 0.2 mm in diameter that spans the distance between Nashville and Mt. Juliet (~22 km) and 
trying to make it fit into a space the size of a soccer ball (about 22 cm). DNA must be compacted 
in such a way that its information is easily accessible so as to facilitate efficient cell function. But 
in much the same way that you can perfectly wrap a pair of headphones into neat coils only to 
find them a tangled mess after a couple of hours in your pocket, DNA will form knots and tangles 
despite the best efforts of a cell to prevent them[22-24]. 
DNA Topoisomerases 
If you could grab a rope-sized, double-stranded, linear molecule of DNA with your hands, you 
could access the information it contained on the inside by pulling the strands apart, starting at 
one end of the molecule and pulling until slowly you were left with one strand in each hand. In 
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doing so, you would notice that as you pulled the strands apart the ends would twist about one 
another to relieve the torsional stress you were creating. The reality of DNA in a cell does not 
allow the ends to rotate, however[6-8, 19]. On the one hand, circular genomes (e.g. those in 
bacteria or mitochondria) do not have ends at all and cannot relieve torsional stress through end 
rotation. On the other hand, linear genomes are constrained through attachments to the 
chromosome scaffold and thus cannot rotate to relieve the tension that arises from opening the 
double helix[8, 19, 21]. 
The cellular response to knots, tangles, and torsional stress is DNA topoisomerases. This 
family of enzymes is ubiquitous through all of life, and interconverts different DNA topoisomers 
by making a transient cut on one (type I topoisomerases) or both strands (type II 
topoisomerases) of the double helix[8, 18, 19, 21, 25, 26]. As a result of their activity, 
topoisomerases can alleviate torsional stress generated by the movement of DNA replication 
forks and transcription complexes, and can resolve DNA knots and tangles generated during 
recombination and replication, respectively[8, 18, 19, 21, 25, 26]. Although type I and type II 
topoisomerases vary in the number of DNA strands they cleave and in their specific mechanism 
of action, they all function by using tyrosine residues that act as nucleophiles when catalyzing 
the DNA cleavage reaction[8, 18, 19, 21, 25, 26]. This scission reaction results in covalent bonds 
formed between the tyrosine residues and the cleaved DNA, which protects the newly formed 
ends from DNA repair enzymes and keeps them in close proximity for religation[8, 18, 19, 21, 
25, 26]. At the conclusion of their catalytic cycles, all topoisomerases return the DNA to its 
previous chemical state, leaving its sequence and chemical nature unaltered and changing only 
its topological state[8, 18, 19, 21, 25, 26]. 
Type I Topoisomerases 
There are three types of type I topoisomerases: type IA, IB, and IC[8, 12, 25]. Type IA 
topoisomerases cut one strand of the DNA, pass the second strand through the break, and 
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reseal the cleaved strand[8, 12, 25]. This action reduces the number of supercoils in the DNA 
by 1, and thus is said to relax the DNA. Most type IA enzymes relax negative supercoils, but 
reverse gyrase, which is found exclusively in thermophilic bacteria and archaea, actively 
introduces positive supercoils into the DNA[25, 27, 28]. Interestingly, type IA enzymes can also 
decatenate single-stranded DNA[12, 25, 29]. Unlike type IA enzymes, type IB topoisomerases 
do not employ a strand passage mechanism and instead cut one strand of the DNA and swivel 
the other about the intact phosphodiester bond. This rotation is controlled by the amount of 
friction and torque contained in the molecule[30]; the tighter the supercoils and the higher the 
tension, the more supercoils that the enzyme relaxes in one cycle. Type IB enzymes can function 
on under- or overwound substrates[25, 31]. The third type, type IC, has only been found in a 
single archaeal genus. It behaves in a manner similar to type IB enzymes, but has little structural 
similarity to them[32]. Except for reverse gyrase, type I topoisomerases act without a high-
energy cofactor such as ATP[25, 28]. 
Humans have several type I topoisomerases. These are topoisomerase I (a type IB enzyme), 
which relaxes negative supercoils and is essential for relieving the torsional stress generated 
during the replication and transcription of nuclear and mitochondrial DNA[25, 33-35]; 
topoisomerase IIIα (a type IA enzyme), which primarily resolves single-stranded DNA tangles 
that sometimes arise during replication, repair and recombination[36-38]; topoisomerase IIIβ (a 
type IA enzyme[39]), which is an RNA topoisomerase[40] that can carry out RNA cleavage[41] 
and strand passage reactions[42]; and mitochondrial topoisomerase I (a type IB enzyme), which 
has functions that are very similar to those of topoisomerase I but is localized exclusively in the 
mitochondria[25, 35]. 
Topoisomerase I is essential in metazoans; complete loss of the enzyme results in 
lethality[43-45]. Its function has traditionally been thought to be limited to DNA nicking and 
closing, resulting in the release of topological stress associated with replication, transcription, 
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repair, and recombination[5, 14, 45]. Recent studies, however, suggest that topoisomerase I has 
pleiotropic functions in cells, playing a role in genomic stability, gene-specific transcription, and 
response to various anticancer agents[45]. 
Type II Topoisomerases 
There are two types of type II topoisomerases, type IIA and IIB, and both detangle, unknot, and 
relax DNA by carrying out strand passage reactions. Although type IIA topoisomerases were 
originally discovered in 1976[46], it was not until 1997 that the first type IIB was identified[47]. 
Type IIA enzymes have been found in every domain of life and in viruses, but to date, type IIB 
topoisomerases are confined mostly to archaea and plants[48]. Both types of enzymes relax 
positive and negative supercoils, share similar ATPase and DNA-cleavage domains, and 
undergo similar catalytic cycles[25, 47], but their primary and tertiary structures differ greatly[25, 
48]. Given the focus of my dissertation, type IIA enzymes will be referred to as type II 
topoisomerases and type IIB enzymes will not be covered further. 
Unlike type I topoisomerases, type II topoisomerases transiently cleave both strands of the 
DNA, creating a staggered cut with 5’ overhangs (Figure 1). To maintain genomic integrity during 
this process, active site tyrosine residues covalently attach to the 5’-termini at each scissile bond; 
these covalent enzyme-cleaved DNA complexes are referred to as cleavage complexes[8, 18, 
19, 21, 25, 26]. It is notable that the two cleavage steps, while coordinated, do not occur 
simultaneously[49-51]. 
Type IIA topoisomerases are composed of various subfamilies, including the eukaryotic type 
II topoisomerases (present in all eukaryotes), DNA gyrases (present in all bacteria, some 
archaea, and eukaryotes with endosymbionts of bacterial origin) and topoisomerases IV (specific 
to bacteria)[48]. Most bacteria have both a DNA gyrase and a topoisomerase IV[52, 53], which 
work in coordination to regulate DNA supercoiling and decatenation[53]. The primary roles of 
DNA gyrase are to remove the positive supercoils that accumulate ahead of replication forks 
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Figure 1. Nucleophilic attack by tyrosine residues catalyzes the double-stranded break 
characteristic of type II topoisomerases. Each topoisomerase II subunit (TopoII) has a 
catalytic tyrosine residue that undergoes a transesterification reaction with the DNA backbone, 
resulting in two single-stranded DNA breaks that are 4-base pairs away and that are stabilized 
through covalent interactions with the enzyme.  
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and to introduce negative supercoils into the DNA[52]. Topoisomerase IV, in turn, removes the 
catenanes that form behind replication forks[52]. Some bacteria, like Mycobacterium 
tuberculosis, have a single type II topoisomerase[31] that behaves as a “hybrid” as it is 
responsible for the tasks that are normally carried out by DNA gyrase and topoisomerase IV[54-
56]. 
Eukaryotic type II topoisomerases, referred henceforth as type II topoisomerases, are 
homodimers. Each protomer subunit can be broken down into three defined domains: the N-
terminal domain, the catalytic core, and the C-terminal domain (Figure 2)[19, 57]. The N-terminal 
domain contains the ATPase domain, which binds and hydrolyzes the high-energy cofactor that 
is necessary for the catalytic cycle of the enzyme[19]. The catalytic core is composed of the 
TOPRIM and DNA breakage-reunion domains, the latter of which contains a winged helix 
domain (WHD)[19, 57]. The catalytic core of the enzyme is sufficient (when dimerized) to carry 
out DNA cleavage and religation, but not strand passage[58]. The C-terminal domain of the 
enzyme contains a nuclear localization signal and sites of phosphorylation[18, 19, 59], and 
although it is not necessary for catalytic activity, it aids in the recognition of the geometry of the 
DNA substrate strand passage[58]. Unlike the N-terminal domain and the catalytic core of type 
II topoisomerases, the C-terminal end is not evolutionarily conserved[19] and imparts the 
enzymes with different characteristics. For example, the C-terminal domain of both isoforms of 
type II topoisomerases expressed in humans (discussed below) provides each one with differing 
abilities to recognize DNA geometry (the three-dimensional arrangement of the helices)[58]. 
The holoenzyme interconverts DNA topoisomers through the coordination of three separable 
dimerization interfaces or gates: the N-gate, the DNA-gate, and the C-gate (Figure 2)[57, 60]. 
Through their coordinated action, type II topoisomerases pass a “transport segment” of DNA, 
captured through the clamp-like closing of the N-gate, through a break they generate on a “gate 
segment” of DNA (Figure 3)[19, 57]. Before any cleavage can take place, the enzyme must be  
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Domain structure of human topoisomerase IIα. The N-terminal domain is shown in 
blue, the catalytic core in red, and the C-terminal domain in green. The N-gate, DNA-gate, and 
C-gate are the dimerization interfaces of the holoenzyme, which act to coordinate the capture, 
cleavage, and release of the DNA segments. The position of the catalytic tyrosine (Y805) within 
the winged helix domain (WHD) is indicated.   
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able to bend the gate segment ~150º[60-62]. Following bending, the enzyme utilizes two tyrosine 
residues in the WHD to create a single-stranded DNA break on each strand of the gate segment, 
resulting in a double-stranded break with a 4-base pair stagger stabilized by phosphotyrosyl 
bonds[8, 18, 19, 62, 63]. As the energy of the phosphodiester bond is conserved by the formation 
of the phosphotyrosyl bond, no energy input is needed for cleavage and religation of the DNA, 
but two divalent metal ions – Mg2+ probably fulfills this role in a physiological setting – are 
required[18, 19, 21, 63, 64]. Although binding of ATP facilitates the capture of the T segment 
and closing of the N-gate[63, 65], hydrolysis is needed to facilitate the conformational changes 
in the enzyme needed for the strand passage step that brings the transport segment through 
DNA-gate formed by the cleaved gate segment[19, 31, 63, 66]. Following strand passage, the 
gate segment is religated and the transport segment is released through the C-gate[57]. 
Hydrolysis of a second ATP molecule helps the enzyme release the gate segment and reset for 
a new round of the catalytic cycle[19, 63, 67], although it is possible to skip the second hydrolysis 
step and catalyze strand passage of a new transport segment without dissociating from the initial 
gate segment[19]. 
Although most lower eukaryotes express only one type II topoisomerase, human cells 
express two closely related isoforms, topoisomerase IIα and IIβ[18]. These isoforms are related 
but are coded for by different genes[6, 14, 68-72] and differ in their molecular weight (170 kDa 
for topoisomerase IIα and 180 kDa for topoisomerase IIβ)[73, 74]. Despite their similarities, 
however, conditional knockout experiments have shown that the β isoform cannot complement 
for a deficiency in α, which is essential for the survival of proliferating cells[19]. The concentration 
of topoisomerase IIα increases over the cell cycle (peaking in G2/M)[75] and plays essential 
roles in DNA replication and chromosome segregation[18, 19, 21]. For this reason, its presence 
is undetectable in quiescent cells[19, 76, 77]. 
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Figure 3. Catalytic cycle of type II topoisomerases. A type II topoisomerase first binds to two 
DNA segments, a gate (green) and a transport (yellow) segment (1). The enzyme bends the 
gate segment (2) and then creates a transient double-stranded break that is stabilized by a 
covalent bond between a catalytic tyrosine residue and the 5’ phosphate of the DNA (3). 
Following the hydrolysis of an ATP molecule, the transport segment is then passed through the 
break (4), and the gate segment is religated (5). Next, the transport segment is released (6). 
Hydrolysis of a second ATP molecule releases the gate segment (7) and readies the enzyme 
for a new round of the cycle.  
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Topoisomerase IIβ maintains a steady concentration irrespective of proliferative state or 
stage of the cell cycle[75] but reaches its highest levels in post-mitotic cells[78]. Although the 
precise cellular function of topoisomerase IIβ is not well defined, it appears to play an important 
role in transcription[79-81] and the expression of hormonally regulated genes[8, 18, 19, 25, 26]. 
Unlike topoisomerase IIα, topoisomerase IIβ is not essential at the cellular level, but its function 
is critical during neural development[82, 83]. 
Type II topoisomerases are inherently dangerous enzymes due to the fact that they cut DNA 
as part of their normal catalytic process[18, 21, 63, 84-87]. To minimize the potential for DNA 
damage, topoisomerases covalently bind to the cleaved DNA ends; this prevents the ends from 
becoming separated within the cell and masks them from DNA repair machinery[18, 21, 63, 86]. 
In addition, the cleavage-ligation equilibrium strongly favors ligation, and cleavage complexes 
are short-lived and readily reversible[18, 59, 66, 88-92]. Yet even with these protections in place, 
the action of type II topoisomerases can result in non-transient DNA damage. If a DNA tracking 
system (such as a replication fork) encounters a cleavage complex, the helicase associated with 
the tracking system can displace the single-stranded DNA that is not covalently attached to the 
type II topoisomerase, preventing the topoisomerase from returning the DNA to its original 
state[93]. 
Most of the time, the DNA damage response can handle low levels of topoisomerase II-
generated DNA damage. However, when the concentration of cleavage complexes in a cell is 
too high, it can overwhelm the repair responses and eventually trigger cell death pathways[18, 
21, 59, 63, 86, 94, 95]. In addition, even the “successful” attempts of a cell at dealing with the 
damage can result in inaccurate repair and damaged chromosomes that can ultimately lead to 
cancer (discussed below)[18, 59, 87, 96-100]. 
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Topoisomerase II Poisons 
Certain kinds of compounds and DNA structures increase the concentration of cleavage 
complexes, which in turn increases the probability that these covalent complexes will be 
converted into double-stranded DNA breaks that require repair[18, 59, 86, 87, 93, 95, 101]. 
Because these agents convert the type II enzymes into cellular toxins that fragment the genome, 
they are called topoisomerase II poisons to distinguish them from catalytic inhibitors that impair 
the overall catalytic activity of the type II enzymes without increasing the concentration of 
cleavage complexes. 
Although topoisomerase II poisons technically inhibit their target – by trapping the cleavage 
complex they impair the completion of the catalytic cycle – they exert their cellular effects by 
inducing or stabilizing cleavage[102]. Conversely, catalytic inhibitors of type II topoisomerases 
can act at any step of the catalytic cycle but their actions result in a decrease in the levels of 
cleavage complexes[102]. Thus, while both classes of drugs rob the cell of the proper functioning 
of type II topoisomerases, poisons lead to an increase in double-stranded DNA breaks[102]. 
Drugs as Topoisomerase II Poisons 
Type II topoisomerases are important cytotoxic targets for anticancer drugs (Figure 4). Despite 
the fact that all human cells express one or both topoisomerase II isoforms, topoisomerase II-
targeting drugs are efficacious against cancer cells primarily for three reasons. First, because 
cancer cells are generally highly proliferative, they express high levels of topoisomerase IIα[19, 
75, 87], leading to the creation of more drug-stabilized cleavage complexes. Second, because 
of the high metabolic rate of cancer cells, replication forks and transcription complexes 
constantly move along the DNA, making it more likely that they will convert cleavage complexes 
to permanent DNA breaks[103]. Third, due to impaired cell cycle checkpoints and DNA damage 
repair pathways in many cancers, malignant cells often are more susceptible to the DNA damage 
caused by topoisomerase II-targeted drugs[87, 104]. 
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Figure 4. Structure of compounds that act as topoisomerase II poisons.  
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 Topoisomerase II poisons are amongst the most widely prescribed anticancer drugs in the 
world[8, 18, 86, 87, 95, 105]. Etoposide, for example, is used to treat testicular, ovarian, and 
lung cancers among others[18, 86, 87, 95, 106, 107]. Doxorubicin is prescribed for treatments 
against breast, bladder, stomach, and thyroid cancers, as well as a variety of other disseminated 
neoplastic conditions[18, 87, 108]. Mitoxantrone is prescribed against a variety of cancers, such 
as breast, prostate, and laryngeal cancers, non-Hodgkin’s lymphoma, and chronic myeloid 
leukemia[18, 87, 98, 109], but its primary use is against acute myeloid leukemia (AML) and 
against the autoimmune disorder multiple sclerosis (MS).  This compound has FDA approval for 
its ability to reduce neurologic disability and the frequency of clinical relapses in patients with 
secondary progressive, progressive relapsing, or worsening relapsing-remitting MS[110]. 
Amsacrine, the last of the examples listed here, is used to treat relapsed acute myeloid 
leukemias and malignant lymphomas[18, 111]. 
Amsacrine was the first anticancer agent shown to act by poisoning topoisomerase II[112]. 
The drug is composed of an acridine ring coupled to a 4’-amino-methane-sulfon-m-anisidide 
head group. Structure-activity studies suggest that the poisoning activity of amsacrine is 
embodied in the head group, while the acridine moiety enhances drug activity primarily by 
promoting strong interactions with DNA[113]. A number of other topoisomerase II-targeting 
agents also utilize an acridine or related aromatic core[8, 18, 86, 87, 95, 105, 114]. Although 
most of these drug cores are attached to an aromatic head group, some agents (such as 
mitoxantrone) lack a head group altogether (Figure 4). 
Etoposide, in particular, has been well studied. It is a derivative of podophyllotoxin, a 
substance naturally found in plants such as the American Mayapple (Podophyllum peltatum), 
which has been used as an anticancer agent in traditional and folk medicine for over a 
millennium[115]. When purified, however, podophyllotoxin and its derivatives in the Mayapple 
demonstrated high toxicities that precluded their use in the clinic[116]. It was later determined 
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that podophyllotoxin bound to tubulin, the monomeric component of microtubules, leading to 
mitotic arrest. The observed toxicities led to a search for synthetic derivatives that retained their 
anticancer activity but that were not as toxic as the natural podophyllotoxins[115, 117-119]. 
 Among the compounds synthesized during the search were 4’-demethylepipodophyllotoxin 
(DEPT) and its derivatives etoposide and teniposide (Figure 5). The latter two have a glucoside 
moiety that prevents their interaction with tubulin[120], completely changing the mechanism of 
action of the compounds and making them less toxic to cells[119]. Etoposide and teniposide 
were finally approved by the FDA as anticancer agents in 1983[119] and 1992, respectively. 
Since its approval, etoposide has been a front-line treatment for many cancers[115], and was 
one of the first anticancer drugs shown to target human type II topoisomerases[115], the first 
being amsacrine[112]. 
 Etoposide affects the activity of human type II topoisomerases through enzyme-drug 
interactions, not through drug-DNA interactions[89, 121, 122], and stabilizes both single- and 
double-stranded cleavage complexes[50]. As determined by saturation transfer difference 
nuclear magnetic resonance spectroscopy, the sugar group does not appear to interact with 
topoisomerase II in the enzyme-DNA complex[123, 124]. In fact, compared to etoposide, DEPT 
induces similar levels of human topoisomerase IIα-mediated DNA cleavage and prevents the 
religation of cleaved DNA to a similar extent[123, 124]. For these reasons, it is reasonable to 
call DEPT the “active core” of etoposide. 
 Outside of the clinic, topoisomerase II poisons make frequent appearances in our diet. For 
example, epigallocatechin gallate (EGCG) is the main active bioflavonoid in green tea[125, 126], 
genistein is an isoflavone present in soy products[125, 127], and curcumin is the main flavoring 
and coloring component of turmeric[128]. Screens of natural products consistently turn up new 
topoisomerase II poisons, including a variety of metabolites from olive plants[129], black 
seed[130], and various fruits and vegetables. 
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Figure 5. Structure of related podophyllotoxins. Rings A-D on etoposide are labeled. The 
sugar group on etoposide is attached at the C4 position.  
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Many dietary poisons are reported to be chemopreventive[131] when consumed as part of a 
regular diet[132], but can also have harmful effects. For example, Asian populations consume 
20-80 mg of genistein per day compared to 1-3 mg in the United States, and have comparatively 
lower rates of breast and prostate cancers[132, 133]. When regularly consumed during 
pregnancy, however, genistein increases the risk of infant leukemias[134]; rates of incidence in 
Japan, for example, are in fact two to three times higher than in the United States[87, 135]. 
Topoisomerase II poison-associated leukemias are discussed in more detail below. 
As widespread as they are, topoisomerase II poisons do not all induce enzyme-mediated 
DNA cleavage the same way. Compounds can be split into interfacial or covalent poisons based 
on their mechanism of action. The differences between these two types of poisons are 
summarized in Table 1. 
Interfacial poisons act non-covalently at the interface between the enzyme and the DNA. 
These compounds physically block the religation of cleaved DNA by wedging themselves into 
the cleaved DNA scissile bonds[49, 102, 136]. Unlike covalent poisons, they are unaffected by 
reducing agents and increase the amount of type II topoisomerase-mediated DNA cleavage 
regardless of whether they are added to cleavage reactions first or last. Prominent examples of 
interfacial poisons include etoposide, amsacrine, and doxorubicin. 
Covalent poisons were originally referred to as redox-dependent poisons because some of 
these compounds undergo redox cycling to enact their effect on the type II topoisomerases[102, 
137]. They act by adducting topoisomerase II at cysteine (and potentially other) residues outside 
of the DNA cleavage-ligation active site of the enzyme[18, 129, 131, 138-140]. Adduction results 
in the cross-linking of both protomers of the enzyme and prevents the N-gate from opening[141, 
142]. Although closing the N-gate does not mechanically increase DNA cleavage, it increases 
the concentration of DNA in the active site of the enzyme and results in higher levels of 
cleavage[143]. 
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Interfacial poisons Covalent poisons 
• Act non-covalently at the active site and 
physically block religation 
• Unaffected by reducing agents 
• Enhance enzyme-mediated DNA 
cleavage when added to the enzyme-
DNA complex 
• Enhance DNA cleavage when incubated 
with the enzyme prior to the addition of 
DNA 
 
• Examples: etoposide, doxorubicin 
• Covalently adduct topoisomerase II at 
sites distal to the active site 
• Lose activity when incubated with 
reducing agents 
• Enhance DNA cleavage only when 
added to the enzyme-DNA complex 
• Inhibit topoisomerase II when incubated 
with the enzyme prior to the addition of 
DNA 
•  
• Examples: curcumin, EGCG 
 
Table 1. Differences between interfacial and covalent poisons of type II topoisomerases.  
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Covalent poisons display several hallmark characteristics that distinguish them from 
interfacial poisons[58, 128-130, 138, 142, 144]. First, reducing agents abrogate the activity of 
these agents[128-130, 144, 145], as redox-cycling is required for the actions of the 
compounds[18, 102]. Furthermore, because covalent poisons act by altering the N-terminal 
portion of the enzyme, they do not enhance DNA cleavage by topoisomerase II constructs that 
lack this domain[58]. Finally, although covalent poisons enhance DNA scission when added to 
the topoisomerase II-DNA complex, they inhibit enzyme-mediated cleavage when incubated with 
the protein prior to the addition of DNA[144, 146]. The adduction of covalent poisons to the 
enzyme and the resulting closure of the N- gate likely contribute but cannot wholly account for 
the inhibition of the enzyme, as closing the N-terminal gate does not prevent binding to linear 
DNA molecules[146] nor does it prevent cleavage[143]. Examples of covalent poisons include 
curcumin and EGCG (Figure 4). 
Topoisomerase II poisons tend to have aromatic rings as a headgroup or core[102, 130, 132, 
144], but it is not a requirement. As covalent poisons act by modifying their target enzymes rather 
than by interacting as “ligands” (as interfacial poisons do), they can tolerate a greater range of 
structural alterations[128, 130, 138, 140, 142, 144, 145, 147, 148]. Interfacial poisons tend to 
have planar ring systems that are DNA-interacting and side chains that are enzyme-
interacting[94, 149, 150], and may or may not be DNA intercalators[151]. 
DNA Lesions as Topoisomerase II Poisons 
The last type of topoisomerase II poison I will cover are DNA lesions and unusual DNA 
structures. As part of their catalytic cycle, type II topoisomerases first test the bendability of the 
DNA substrate. If they can bend the DNA, they can cut at that site[60, 62]. DNA lesions and 
structures that increase the flexibility/bendability of the double helix tend to be good cleavage 
substrates and facilitate the forward rate of cleavage, thereby leading to an increased number 
of cleavage complexes in a cell[18, 92, 152-159]. The Osheroff lab has previously characterized
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Figure 6. Structures of DNA lesions that act as topoisomerase II poisons. εdC, 3,N4-
ethenodeoxycytidine; rC, 2′-ribocytidine; εrC, 3,N4-etheno- 2′-ribocytidine.  
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a wide variety of DNA lesions as topoisomerase II poisons, including abasic sites[157, 160] and 
exocyclic lesions such as 3,N4-ethenodeoxycytidine (εdC), 3,N4-etheno-2’-ribocytidine (εrC), and 
1,N2-ethenodeoxyguanosine (εdG)[159] (Figure 6). Although the only way to determine whether 
or not a particular lesion will induce topoisomerase II-mediated DNA cleavage is to test it 
experimentally, lesions that are small, that do not create kinks or distort the DNA, or that do not 
increase the flexibility of the double helix tend not to act as topoisomerase II poisons[157]. 
Examples of such lesions are N6-methyladenine, 8-oxoguanine, and 8-oxoadenine (Figure 
7)[157]. 
Type II Topoisomerases and Cancer 
Although topoisomerase II poisons are extremely useful in treating cancers and other diseases 
such as multiple sclerosis, their use can unfortunately lead to a variety of mechanism-induced 
(i.e., topoisomerase II-generated) toxicities. These arise because of the difficulty of targeting 
drugs such as etoposide specifically to cancer cells[18, 86, 87, 106] and because all cell types 
express one or both topoisomerase II isoforms[21, 25]. 
Shortly after etoposide and teniposide were first introduced into the clinic in the 1980s, 
physicians began observing a new form of secondary leukemias that was characterized by 
balanced chromosomal translocations[161, 162]. Over 10% of patients treated with etoposide 
went on to develop therapy-associated acute myeloid leukemias (t-AML)[84, 87, 163-166]. 
Thankfully, once the high-risk regimens were identified[84, 167], the number of affected patients 
dropped to ~2-3%[87]. 
A variety of translocations or mutations can give rise to the highly heterogeneous AML, the 
most common acute leukemia in adults[168]. t-AMLs associated with topoisomerase II-targeting 
drugs display a balanced translocation that includes the mixed lineage leukemia (MLL) gene on 
chromosomal band 11q23[84, 87, 169], which codes for a histone methyltransferase[170]. De 
novo AMLs have an 8.3-kb breakpoint cluster region (BCR) in MLL[84, 87], but the chromosomal 
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Figure 7. Structures of DNA lesions that do not act as topoisomerase II poisons.  
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breakpoints associated with t-AMLs are concentrated on the 1-kb telomeric end of the de novo 
BCR[87, 171]. Over 80 translocation partners have been described for MLL, but AF4 and AF9 
are the most prevalent partners associated with topoisomerase II-targeting drugs[171]. Whether 
or not the translocation sites in MLL or its partner are located within a BCR, they are located 
within a few base pairs of drug-induced topoisomerase II DNA cleavage sites[169, 172] and are 
hypothesized to arise directly as a result of illegitimate repair following cleavage by a type II 
topoisomerase[172-174],[175, 176]. 
Another important type of topoisomerase II poison-related leukemia, therapy-associated 
acute promyelocytic leukemia (t-APL), arises from a balanced translocation between intron 6 of 
the promyelocytic leukemia (PML) gene on chromosome 15 and intron 2 of the retinoic acid 
receptor α (RARA) gene on chromosome 17. t-APL is associated with the use of mitoxantrone 
in treating breast cancers and MS; in fact, MS patients account for ~16% of t-APL patients[87, 
177, 178]. The remarkable feature of t-APLs is that ~60% of patients display breakage in PML 
within an 8-bp BCR, whereas de novo APLs have a BCR that is about 1 kb in length[87, 98, 
177]. In contrast, the breakpoints at RARA occur at a variety of locations along the 17-kb-long 
intron 2[98, 99, 177, 179]. As with AML, the breakage sites on the translocation partners (PML 
and RARA for APL) are located on or in close proximity to drug-induced (mitoxantrone, 
etoposide, and epirubicin, an analog of doxorubicin) type II topoisomerase cleavage sites[87, 
98, 99, 177, 180]. Although the specific mechanism by which drug-induced topoisomerase II-
mediated DNA cleavage triggers the leukemic translocation is controversial, considerable 
circumstantial evidence suggests that sites cleaved by the enzyme go on to generate the 
translocation breakpoint[81, 87, 162, 176, 177]. 
Specifically, topoisomerase IIβ has been implicated in this process. Some of the first 
indications of the involvement of the β isoform came from experiments using skin-specific top2b- 
knockout mice, which had a lower incidence of secondary malignancies compared to wild-type 
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(WT) mice after treatment with etoposide[181]. As discussed above, topoisomerase IIβ plays a 
larger role in transcription than topoisomerase IIα. Recent insights on transcription suggest that 
genes are transcribed in “factories”, or hubs of transcription machinery that are clustered with 
others that are engaged on different templates[182]. Given that MLL, AF9, and AF4 are 
transcribed in the same factory, it has been suggested that illegitimate repair and recombination 
between these genes can occur following transcription-associated topoisomerase IIβ cleavage 
that has been stabilized by topoisomerase II poisons[87, 171]. Combined with the fact that 
topoisomerase IIβ has also been implicated in the cardiotoxicity associated with anthracyclines 
like doxorubicin[86, 183, 184], developing drugs that display strong activity and higher specificity 
for the α isoform is a desirable goal. 
Scope of the Dissertation 
Many anticancer drugs have very undesirable side effects because they oftentimes affect non-
cancer cells almost as much as they affect cancerous cells[59, 87, 162, 181, 185]. Because all 
cells express at least one isoform of human type II topoisomerases[18, 19, 86, 87], all cells are 
at least somewhat susceptible to the effects of topoisomerase II poisons, especially proliferative 
tissues (hair, skin, gastrointestinal tract, etc.) with high cell turnover[186]. Such widespread 
susceptibility to this and other classes of cytotoxic anticancer drugs necessitates the generation 
of new or improved drugs or delivery systems that are better targeted to cancer cells. 
An example of drug modifications designed to target cancer cells are polyamine-containing 
etoposide derivatives. As many cancers upregulate the polyamine transport system[187, 188], 
cancer cells preferentially uptake the polyamine-modified derivatives compared to non-cancer 
cells[188-190]. Other examples of polymer conjugates include polyethylene glycol (PEG), N-(2-
Hydroxypropyl) methacrylamide (HPMA), polylactic-co-glycolic acid (PLGA), and 
polyamidoamine (PAMAM)[191]. An example of an improved drug delivery system is the 
nanoparticle, a non-toxic polymer shell that can be designed to encapsulate anticancer drugs 
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and to release its cargo only when it reaches its cancer cell targets[192-194]. Additional drug 
delivery approaches include drug-loaded hydrogels[195], receptor-based targeting[194], and 
antibody-drug conjugates[196]. This dissertation describes two other approaches to reducing 
off-target effects and improving cancer-cell specificity of topoisomerase II poisons. 
Chapter 1 of the dissertation covers the background literature, and sets the stage for 
discussion of two approaches for improving the specificity of topoisomerase II-targeting 
anticancer drugs. Chapter 2 discusses the materials and methods employed for all the 
experiments in the dissertation. Chapter 3 delves into whether novel trifluoromethylated 9-
amino-3,4-dihydroacridin-1(2H)-one derivatives could serve as a scaffold for new topoisomerase 
II-targeting drugs. It explores whether the compounds increase DNA cleavage mediated by 
topoisomerase IIα, and, if they do, whether those compounds act as covalent or interfacial 
topoisomerase II poisons. This material has been published in Bioorganic & Medicinal Chemistry 
Letters[197]. Chapter 4 describes the ability of topoisomerase IIα and IIβ to mediate DNA 
cleavage on duplexes containing oligonucleotide-linked topoisomerase II poisons (OTIs). These 
drug-DNA hybrids are designed to target specific DNA sequences, and are therefore proposed 
as a new approach to targeting cancer cells while reducing the cytotoxicity of treatment. The 
majority of data in this chapter have been published in Nucleic Acids Research[198]. Chapter 5 
provides an overview of the results and an outlook on the next steps for these and for related 
research avenues.  
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Chapter 2: Materials and Methods 
Biology 
Enzymes 
Recombinant wild-type human topoisomerase IIα and topoisomerase IIβ and wild-type yeast 
topoisomerase II and the etoposide-resistant H1011Y mutant yeast type II enzyme were 
expressed in Saccharomyces cerevisiae JEL-1Δtop1 and purified as described previously[153, 
199-201]. This mutation was originally published as H1012Y[201]. The numbering of the 
mutation was changed to H1011Y in 2001[202] to accommodate a reported error in the original 
amino acid sequence of S. cerevisiae topoisomerase II[203]. The catalytic core of human 
topoisomerase IIα (residues 431−1193) was a gift from J. Deweese (Lipscomb University 
College of Pharmacy) and was expressed and purified as described previously[153, 199, 200]. 
Human enzymes were stored at -80 °C as 1.5 mg/mL stocks in 50 mM Tris-HCl, pH 7.9, 0.1 mM 
ethylenediaminetetraacetic acid (EDTA), 750 mM KCl, and 40% glycerol, and yeast enzymes 
were stored as 2 mg/mL stocks in 10 mM Tris-HCl, pH 7.7, 1 mM ethylene glycol-bis(β-
aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), 1 mM EDTA, 750 mM KCl, 30% glycerol, 
and 0.5 mM dithiothreitol (DTT). The residual concentration of DTT was <2 μM in final reaction 
mixtures. Calf thymus topoisomerase I was obtained from Invitrogen. 
Materials 
Analytical grade etoposide was purchased from Sigma-Aldrich and stored at room temperature 
as a 40 mM stock solution in 100% dimethyl sulfoxide (DMSO). Negatively supercoiled pBR322 
DNA was prepared from Escherichia coli using a Plasmid Mega Kit (Qiagen) as described by the 
manufacturer. Analytical grade etoposide was purchased from Sigma-Aldrich. Amsacrine and 
acridine were a gift from Dr. David Graves (University of Alabama at Birmingham). 
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Oligonucleotides and OTIs 
Three DNA sequences were used to create a series of oligonucleotide duplexes. The first 
sequence was a 50-mer that encompassed bases 1461-1510 of intron 6 of PML, and contained 
a previously identified, 8-base pairs-long topoisomerase II cleavage hotspot (bases 1482-1489) 
associated with the generation of t-APLs[98]. The hotspot contains a strong topoisomerase II-
mediated cleavage site that is represented in position 24-25 on the top (or target) strand of the 
oligonucleotide and to 26-27 on the bottom strand (either an unmodified oligonucleotide or an 
OTI). Top strand: 5’-
CTTTGTTCCTCATTCTGACTGAGCCCTAGCCTTGGTCACACACTGAGCAG-3’. Bottom 
strand: 5’-CTGCTCAGTGTGTGACCAAGGCTAGGGCTCAGTCAGAATGAGGAACAAAG -3’. 
OTI28, OTI29, OTI33, and OTI23 had the same sequence as the PML 50-mer bottom strand, 
except that the active core of etoposide (4’-demethylepipodophyllotoxin, DEPT) was linked to 
the oligonucleotides at positions 28, 29, 33, and 23, respectively. A 50-mer bottom strand that 
contained the linker with no attached drug (LIN28) or a tetrahydrofuran abasic site analog (AP28) 
at position 28 also were synthesized. 
The second sequence utilized was a 50-mer that spanned a previously identified 
translocation between PML and RARA in a patient with t-APL[99]. Top strand: 5’-
CTTTGTTCCTCATTCTGACTGAGCCCTA/GTCTGCCATCCTAACCTTCCAT-3’, made up of 
bases 1461-1488 of intron 6 of PML (before the slash) and bases 12039-12060 of intron 2 of 
RARA (after the slash) The bottom strand was fully complementary. Bottom strand: 5’-
ATGGAAGGTTAGGATGGCAGAC\TAGGGCTCAGTCAGAATGAGGAACAAAG-3’. 
Sequences from RARA are located to the left of the backslash and sequences from PML are 
located to the right of the backslash. A 50-mer OTI with the bottom strand sequence was 
synthesized and contained a linked DEPT at position 29. Two additional OTIs based on the 
same sequence, a 30-mer (5’-TAAGACTGACTCGGGATCAGACGGTAGGAT-3’) and a 20-mer 
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(5-CTGACTCGGGATCAGACGGT-3’), were synthesized. These sequences contained 10 or 15 
fewer bases from each of the 5’- and 3’-termini of the 50-mer, respectively, but had the linked 
DEPT at the same nucleotide as the 50-mer. 
The third oligonucleotide was a 50-mer that corresponded to bases 12011-12060 of intron 2 
of the parental RARA sequence that spanned a patient-derived translocation breakage point (at 
12038-12039, corresponding to 28-29 on the oligonucleotide) observed in a patient[99]. Top 
strand: 5’- CAGAAAGGGGCAACTTCATCAGACACCCGTCTGCCATCCTAACCTTCCAT-3’. All 
the non-OTI oligonucleotides were synthesized by Sigma-Aldrich unless specified. 
Six oligonucleotides were designed that contained a single-base difference in the WT PML 
top strand sequence such that, when annealed to a WT PML bottom strand, OTI28, OTI29, 
OTI33, or OTI23, each duplex would contain a single mismatch. The oligonucleotides were 
named using the convention X#Y, where X is the WT base, # is the position of the changed base 
(5’-3’), and Y is the new base. Thus, the six “mismatch” oligonucleotides were C19G, G23A, 
C24G, C24A, C24T, and C25G. Duplexes containing a mismatch are referred to simply by the 
name of the mismatch oligonucleotide. The mismatch oligonucleotides were designed such that 
the mismatches were the most disruptive as measured by DNA breathing. For example, the WT 
base pair at position 19 on a PML duplex is C:G. Since the base pair that would generate the 
highest amount of breathing is G:G[204], the base at position 19 on the top strand was changed 
from C to G. Three base changes, resulting in G:G, A:G, and T:G mismatches, were generated 
for position 24.  
Oligonucleotides were synthesized by our collaborators at GlaxoSmithKline (GSK), except 
for AP28, which was obtained from Eurofins MWG Operon, and the mismatch oligonucleotides, 
which were obtained from Sigma-Aldrich. 
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Cleavage of Plasmid DNA 
DNA cleavage reactions were carried out using the procedure of Fortune and Osheroff[205]. 
Reaction mixtures contained 10.6 nM negatively supercoiled pBR322 plasmid DNA and 290 nM 
human topoisomerase IIα or 850 nM human topoisomerase IIα catalytic core in a final volume 
of 20 µL of human DNA cleavage buffer[10 mM Tris-HCl, pH 7.9, 5 mM MgCl2, 100 mM KCl, 0.1 
mM EDTA, and 2.5% (v/v) glycerol]. Reactions were carried out in the presence of 0-1000 µM 
trifluoromethylated 9-amino acridin-1(2H)-one derivatives or acridine, 0-50 µM amsacrine, or 0-
200 µM etoposide. Mixtures were incubated for 6 min at 37 ºC and enzyme-DNA cleavage 
complexes were trapped by the addition of 2 μL of 5% sodium dodecyl sulfate (SDS) followed 
by 2 μL of 250 mM Na2EDTA, pH 8.0. Proteinase K (2 μL of a 0.8 mg/mL solution) was added, 
and samples were incubated for 30 min at 45 ºC to digest the enzyme. Samples were mixed 
with 2 µL of agarose loading dye [60% sucrose (w/v), 10 mM Tris-HCl, pH 7.9, 0.5% 
bromophenol blue, 0.5% xylene cyanol], heated for 2 min at 45 ºC, and subjected to 
electrophoresis using 1% agarose gels in 40 mM Tris-acetate, pH 8.3 and 2 mM EDTA (TAE) 
containing 0.5 μg/mL ethidium bromide. DNA bands were visualized by UV light and quantified 
using an Alpha Innotech digital imaging system. Double-stranded DNA cleavage was monitored 
by the conversion of supercoiled plasmid to linear molecules. 
To examine the effects of reducing agents on the activity of the trifluoromethylated 9-amino 
acridin-1(2H)-one derivatives, 0.5 mM DTT was included in DNA cleavage reactions that were 
carried out in the presence of 1 mM compound. Reactions were stopped, processed, and 
analyzed as described above. 
To assess the effects of the trifluoromethylated 9-amino acridin-1(2H)-one derivatives on 
human topoisomerase IIα prior to the addition of DNA, 220 nM enzyme was incubated in the 
presence of 1 mM compound for 0-5 min at 37 ºC in a total volume of 18 μL of cleavage buffer. 
DNA cleavage was initiated by the addition of 10.6 nM negatively supercoiled pBR322 DNA 
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(final concentration) to reaction mixtures (final volume of 20 μL), and samples were incubated 
for 6 min at 37 ºC. Reactions were stopped, processed, and analyzed as described above. 
Cleavage of Oligonucleotides 
DNA cleavage reactions were carried out by a modification of the procedure of Deweese et 
al.[92]. The top (target) strand of each double-stranded oligonucleotide was labeled on its 5’-
terminus in 30 µL reactions containing 200 pmol of oligonucleotide, 1 µL of T4 polynucleotide 
kinase (PNK) (New England BioLabs), 3 µL of T4 PNK buffer as supplied by the manufacturer, 
and 2 µL of [γ-32P]ATP (~5000 Ci/mmol, Perkin Elmer). The cpm/µL of each labeled 
oligonucleotide was adjusted so that the intensity of bands on the polyacrylamide gel was 
reflective of topoisomerase II-mediated DNA cleavage and not differences in labeling efficiency. 
Reactions were incubated at 37 ºC for 60 min, with an additional 1 µL of T4 PNK added after the 
first 30 min. Radiolabeled oligonucleotides were purified with Qiagen Mini Quick Spin columns 
according to the manufacturer’s instructions. Top/target and bottom/OTI oligonucleotides were 
annealed by incubating them at a 1:1 ratio (0.5 pmol/µL) at 70 ºC for 10 min, followed by a 
gradual cool down (-4 ºC/min) to 37 ºC. 
DNA cleavage reaction mixtures contained 2 pmol of double-stranded oligonucleotides and 
440 nM human topoisomerase IIα, 415 nM human topoisomerase IIβ, 600 nM wild-type yeast 
topoisomerase II, or 1,340 nM H1011Y mutant yeast topoisomerase II in a final volume of 20 µL 
of human or yeast[50 mM Tris-HCl pH 7.9, 25 mM MgCl2, 500 mM NaCl, 0.5 mM disodium 
ethylenediaminetetraacetic acid (Na2EDTA), pH 8.0, 12.5% (v/v) glycerol] cleavage buffer. 
(Levels of yeast enzymes in DNA cleavage assays were adjusted to yield similar levels of 
background DNA cleavage.) Reactions were initiated by the addition of enzyme. Samples were 
incubated at 37 ºC for 10 min (topoisomerase IIα and yeast topoisomerase II) or 1 min 
(topoisomerase IIβ), and reactions were stopped by the addition of 2 µL of 10% SDS and 2 µL 
of 250 mM Na2EDTA. Samples were incubated with proteinase K for 30 min at 37 ºC to digest 
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the type II enzyme. DNA cleavage products were precipitated with ethanol, mixed with 5 µL of 
80% (v/v) formamide, 100 mM Tris-borate and 2 mM EDTA (TBE), and 10% agarose loading 
dye, and heated to 75 ºC for 2 min. DNA samples were resolved on 14% denaturing 
polyacrylamide gels and were visualized and quantified using a Bio-Rad Molecular Imager. 
All double-stranded oligonucleotides contained unmodified (non-OTI) top/target strands that 
were radiolabeled at the 5’ end. Bottom strands were either unmodified (non-OTI) or contained 
a linked DEPT (OTI), linker alone (LIN28), or a tetrahydrofuran (AP28). In some cases, 
unmodified double-stranded oligonucleotides (non-OTI duplexes) were treated with 0-500 µM 
etoposide. 
Intercalation of Compounds into Plasmid DNA 
DNA intercalation reactions were carried out using the protocol of Fortune et al.[206] Calf thymus 
DNA topoisomerase I (0.4 U) and 5.3 nM pBR322 were incubated in 20 µL of cleavage buffer 
that contained 175 mM rather than 100 mM KCl. Reactions were carried out in the absence or 
presence of 1 mM trifluoromethylated 9-amino acridin-1(2H)-one derivatives. Ethidium bromide 
(10 µM), amsacrine (500 µM), and acridine (500 µM), which are well-characterized intercalators, 
were used as positive controls, and etoposide (500 µM), a non-intercalative topoisomerase II 
poison, was used as a negative control. Mixtures were incubated for 15 min at 37 ºC, and 
reactions were stopped by the addition of 3 μL of 0.77% SDS and 77.5 mM Na2EDTA, pH 8.0. 
Samples were extracted using 23 µL of phenol:chloroform:isoamyl alcohol (25:24:1), and the 
aqueous layer was mixed with 2 µL of agarose loading dye. Intercalation products were resolved 
on a 1% agarose gel in TBE. Gels were stained for 30 min using 1 μg/mL ethidium bromide and 
rinsed in deionized water for 10 min, and DNA bands were visualized as described above. DNA 
intercalation was monitored by the conversion of relaxed to supercoiled plasmid molecules.  
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Ligation of Cleaved Plasmid DNA 
DNA ligation mediated by human topoisomerase IIα was monitored according to the procedure 
of Byl et al.[207] DNA cleavage-ligation equilibria were established for 6 min at 37 ºC as 
described above in the absence or presence of 1 mM trifluoromethylated 9-amino acridin-1(2H)-
one derivative, 50 µM amsacrine, or 50 µM etoposide. Ligation was initiated by placing the 
reaction mixtures on ice. The temperature shift allows ligation but prevents the formation of new 
cleavage complexes[208]. Reactions were terminated after 0-15 s by the addition of 2 μL of 5% 
SDS followed by 2 μL of 250 mM Na2EDTA, pH 8.0. Samples were processed, resolved on 1% 
agarose gels in TAE with ethidium bromide, and analyzed as described above. Ligation was 
monitored by the loss of linear DNA. 
Ligation of Cleaved Oligonucleotides 
DNA ligation assays were carried out with topoisomerase IIα by a modification of the procedure 
of Byl et al.[207]. DNA cleavage/ligation equilibria were established as in the Cleavage of 
Oligonucleotides section. Reactions contained either an unmodified double-stranded 
oligonucleotide in the presence of 500 µM etoposide or an unmodified top (i.e. target) strand 
hybridized to an OTI28 bottom strand. Ligation was initiated by placing the reaction mixtures on 
ice and were stopped by the addition of 2 µL of 10% SDS followed by 2 µL of 250 mM Na2EDTA. 
Samples were processed, resolved on denaturing polyacrylamide gels, and analyzed as 
described above. The percent DNA cleavage at time zero was set to 100%, and the rate of 
ligation was determined by quantifying the loss of cleaved DNA over time. 
Persistence of Oligonucleotide-Enzyme Cleavage Complexes 
DNA cleavage/ligation equilibria were established using topoisomerase IIα and oligonucleotide 
substrates as described above. Persistence reactions were carried out by modification of the 
procedure of Bandele and Osheroff[209]. Reactions contained either an unmodified double-
stranded oligonucleotide in the presence of 500 µM etoposide or an unmodified top strand 
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hybridized to an OTI28 bottom strand. Assay mixtures were diluted 20-fold with cleavage buffer 
incubated at 37 ºC for up to 120 min. Reactions were stopped and samples were processed, 
resolved on denaturing polyacrylamide gels, and analyzed as described above. The percent 
DNA cleavage at time zero was set to 100%, and the stability of the cleavage complexes was 
determined by quantifying the loss of cleaved DNA over time. 
Trifluoromethylated 9-Amino-3,4-Dihydroacridin-1(2H)-One Chemistry 
The following procedures were carried out by Alexis Sledge and Amine Laradji from the 
laboratory of Dr. Cosmas Okoro, a collaborator at Tennessee State University. 
The trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-one derivatives (referred to as 
trifluoromethylated 9-amino acridin-2-ones) were prepared from the corresponding 
enaminobenzonitrile[210], following the procedure published by Gregory M. Shustske and 
coworkers[211]. All compounds were resuspended in 100% DMSO. 
9-Amino-3-(trifluoromethyl)-3,4-dihydro-2H-acridin-1-one (Compound 1) 
A 50-mL round-bottom flask fitted with a condenser and magnetic stirrer was flushed with 
nitrogen. 5-H-2-(3-oxo-5-(trifluoromethyl)cyclohex-1-enylamino)benzonitrile (1 mmol) was 
placed in the flask along with CuCl (0.0165 g, 0.167 mmol), anhydrous K2CO3 (0.046 g, 0.333 
mmol), and toluene (10 mL), and the resulting mixture was refluxed for 6 h. The reaction was 
determined to be complete after 6 h as monitored by thin layer chromatography (TLC). The hot 
mixture was filtered into hexane, and the precipitate was separated and removed by filtration. 
The precipitate was washed with water and the filter cake was recrystallized from methanol. 
9-Amino-6-methyl-3-trifluoromethyl-3,4-dihydro-2H-acridin-1-one (Compound 2) 
A similar procedure described for the preparation of compound 1 was used, except that 4-methyl-
2-(3-oxo-5-(trifluoromethyl)cyclohex-1-enylamino)benzonitrile replaced the 5-H compound and 
tetrahydrofuran replaced the toluene in the reaction mixture. 
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9-Amino-7-chloro-3-(trifluoromethyl)-3,4-dihydro-2H-acridin-1-one (Compound 3) 
A similar procedure described for the preparation of compound 1 was used, except that 5-chloro-
2-(3-oxo-5-(trifluoromethyl)cyclohex-1-enylamino)benzonitrile replaced the 5-H compound in the 
reaction mixture. 
9-Amino-7-fluoro-3-(trifluoromethyl)-3,4-dihydro-2H-acridin-1-one (Compound 4) 
A similar procedure described for the preparation of compound 1 was used, except that 5-fluoro-
2-(3-oxo-5-(trifluoromethyl)cyclohex-1-enylamino)benzonitrile replaced the 5-H compound and 
tetrahydrofuran replaced the toluene in the reaction mixture. 
9-Amino-7-nitro-3-(trifluoromethyl)-3,4-dihydro-2H-acridin-1-one (Compound 5) 
A similar procedure described for the preparation of compound 1 was used, except that 5-nitro-
2-(3-oxo-5-(trifluoromethyl)cyclohex-1-enylamino)benzonitrile replaced the 5-H compound and 
tetrahydrofuran replaced the toluene in the reaction mixture. 
9-Amino-7-bromo-3-(trifluoromethyl)-3,4-dihydro-2H-acridin-1-one (Compound 6) 
A similar procedure described for the preparation of compound 1 was used, except that 5-bromo-
2-(3-oxo-5-(trifluoromethyl)cyclohex-1-enylamino)benzonitrile replaced the 5-H compound and 
tetrahydrofuran replaced the toluene in the reaction mixture. 
3-(trifluoromethyl)-3,4-dihydro-2H-acridin-1-one (Compound 7) 
Aqueous HCl (1 mL of 1 N) was added to a mixture of 2-aminobenzaldehyde (1 mmol) and 5-
(trifluoromethyl)cyclohexane-1,3-dione (1 mmol). The resulting mixture was heated at 75 ºC for 
2 h. The reaction was determined to be complete after 6 h as monitored by TLC, and the resulting 
suspension was neutralized with 1 mL of 1 M NaOH. The precipitate was filtered, washed thrice 
with 6 mL water, air-dried, and recrystallized from ethanol. 
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OTI Chemistry 
The following procedures were carried out by Drs. Sabine Fenner, Steven Ratcliffe, Alberto 
Isidro-Llobet, and Michael Hann, collaborators at GSK. 
A scheme for the synthesis of OTIs linked to the etoposide core is shown in Figure 8. On the 
basis of the molecular modeling results, an 8-carbon linker was utilized, which consisted of a 
terminal alkyne moiety attached to the C5 position of a cytosine or thymine residue to attach an 
azide-modified DEPT (1) via copper-catalyzed click chemistry. 
Synthesis of the activated etoposide core, shown in the top portion of Figure 8, started with 
commercially available DEPT (1) (ABCAM Biochemicals). Compound 1 subsequently was 
protected with carboxybenzyl (Cbz) at the 4’-OH using benzyl chloroformate and triethylamine 
in dichloromethane[103]. The desired product 2 was obtained in 91% isolated yield. The 4-OH 
of 2 was reacted with monotosylated diethylene glycol[104] using boron trifluoride etherate in 
dichloromethane at -20 ºC to generate 3a-b in 72% yield as a mixture of two epimers. Removal 
of the Cbz protecting group under hydrogenation reaction conditions with Pd/C in ethyl acetate 
resulted in 4a-b in 94% yield. The tosyl group was displaced with sodium azide in dimethyl 
formamide at 60 ºC and generated 5a-b in 67% yield as a mixture of two epimers. The desired 
azide coupling partner 5a was purified as a single epimer by chiral chromatography. 
The synthesis of OTIs, exemplified by 7, is shown in the bottom portion of Figure 8. 
Oligonucleotide 6, which included an alkyne-modified cytosine (purchased from Jena 
Biosciences) at position 28, was synthesized by well-established solid phase methods. Copper- 
catalyzed click chemistry was employed to synthesize OTI28 (7) using a preformed complex of 
copper bromide and Tris(benzyltriazolylmethyl)amine (TBTA) in a mixture of DMSO, tert-butanol 
and water. A final isolated yield of 46% was obtained after HPLC purification. Subsequent OTIs  
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Figure 8. Schematic of the synthesis of OTIs. The synthesis of OTI28 (7) is shown as an 
example. DEPT (1) was protected with carboxybenzyl (Cbz) at the 4’-OH using benzyl 
chloroformate and triethylamine in dichloromethane to yield 2. The 4-OH of 2 was reacted with 
monotosylated diethylene glycol using boron trifluoride etherate in dichloromethane at -20 ºC to 
generate 3a-b as a mixture of two epimers. Removal of the Cbz protecting group under 
hydrogenation reaction conditions with Pd/C in ethanol resulted in 4a-b. Continued next page.  
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The tosyl group was displaced with sodium azide in dimethyl formamide at 60 ºC to generate 
5a-b as a mixture of two epimers. The desired azide coupling partner 5a was purified as a single 
epimer by chiral chromatography. Copper-catalyzed click chemistry was used to couple 5a to 
oligonucleotide 6 (which included an alkyne-modified cytosine at position 28) to yield OTI28 (7). 
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were synthesized in a similar manner with an alkyne-modified thymine (Integrated DNA 
Technologies) at positions 23, 29, or 33 as the point of attachment for the linked DEPT, yielding 
OTI23, OTI29, and OTI33, respectively. Three additional OTIs of different lengths, a 50-mer, 30-
mer, and 20-mer, were directed against a patient-derived PML-RARA breakpoint sequence (see 
below). The linked etoposide core in the 50-mer was positioned at the same base as OTI29. 
Purity of all oligonucleotides ranged from 90% to 99.9%. 
Molecular modeling 
These procedures were carried out by Dr. Benjamin Bax at GSK. 
To guide the placement and length of the chemical linker that joined the active DEPT core of 
etoposide to the modified base in the oligonucleotides, structures of OTI complexes were 
modeled using Coot[212], MOE[213], and Maestro (Schrödinger Release 2017-2: Maestro, 
Schrödinger, LLC, New York, NY, 2017). Models were based on the crystal structures of the 
human topoisomerase IIβ and topoisomerase IIα cleavage complexes with DNA and two 
etoposide molecules (one at each scissile bond) (PDB code: 3QX3[136] and PDB code: 
5GWK[214], respectively), and the Staphylococcus aureus gyrase-DNA complex one etoposide 
molecule (PDB code: 5CDN)[215] (Figure 9). The positions of the etoposide molecules in the 
DNA complexes with human and bacterial enzymes are essentially the same (Figure 9). 
With two etoposide molecules bound (one at each scissile bond), the DNA gate seems to be 
wedged open with a relatively small area buried between the two protein subunits at the DNA 
gate[136, 215] (Figure 10). However, a much larger area is buried between the two subunits at 
the DNA gate (Figure 10) in the S. aureus DNA gyrase with one etoposide bound, and the 
common CRsym conformation is observed[215]. Given that this conformation has also been 
observed with eukaryotic type IIA topoisomerases[64, 215], the subunits in our modeled 
topoisomerase IIβ complex with one etoposide were modeled in a CRsym conformation (Figure  
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Figure 9. Similarity of the etoposide binding site in crystal structures of DNA cleavage 
complexes formed with human topoisomerase IIβ and S. aureus gyrase. (A) Structure of 
human topoisomerase IIβ (PDB code: 3QX3) with an etoposide molecule (cyan carbons) bound. 
One topoisomerase II protomer subunit has red carbons (TOPRIM domain) or blue carbons. 
Carbons from the DNA segment bound to this subunit are shown in green. The second 
topoisomerase II protomer subunit is shown in gray. Carbons from the DNA segment bound to 
this subunit are shown in black. Residues close to the etoposide are shown as sticks. (B) 
Structure of S. aureus gyrase (PDB code: 5CDN) with an etoposide molecule (marine carbons) 
bound. (C) Comparison of A and B. Note the difference in positions of the catalytic tyrosine from 
the subunits shown in blue and gray. These data were generated by collaborators at GSK. 
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11; notice the movement of the catalytic tyrosine residues between the complex with one and 
two etoposides relative to movement of the two subunits). 
The alkyne moiety of the linker on the C5 position of the modified base projects ~2.6 Å further 
than the methyl on the C5 position of a thymine or a methylated cytosine (Figure 10). In modeling 
studies, the modified base was covalently attached to DEPT with a linker (Figures 11E,F and 8), 
and was modeled at four positions adjacent to the cleavage site on each strand (Figure 12): -2, 
-1, +1, and +2 on the cleaved strand, and +3*, +4*, +5*, and +6* on the non-cleaved (or OTI) 
strand. The rod-like alkyne moiety was observed to clash with protein residues when positioned 
on the cleaved strand at the -2, -1, +1, or +2 positions. However, modeling the rod-like alkyne 
moiety on the uncleaved strand at the +3*, +4*, +5*, or +6* position did not result in any clashes 
(Figure 12). These models indicate that cleavage is most likely to occur on the target strand 
rather than the OTI strand itself. Two different lengths of linkers were modeled, but a much 
longer linker (Figure 11E,F) was needed to enable the linked etoposide core to reach back to 
the binding site in the DNA from the +3*, +4*, +5*, or +6* positions.  
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Figure 10. Comparisons of etoposide crystal structures. (A,B) Structure of human 
topoisomerase IIβ (PDB code: 3QX3) with a bound etoposide molecule. The colored subunit has 
been superimposed on the grey subunit in B (the complex displays C2 symmetry). DNA, orange; 
G DNA, gate DNA. (C,D) A 2.8 Å-crystal structure of S. aureus gyrase (PDB code: 5CDN) bound 
to one etoposide molecule. The colored subunit in D has been superimposed on the grey 
subunit. Note the relative shift in the subunit that was not superimposed (this complex is 
asymmetric). (E,F) A 2.45 Å-crystal structure of S. aureus gyrase (PDB code: 5CDP) with nicked 
DNA and one etoposide bound. The colored subunit in F has been superimposed on the grey 
subunit. Note that this complex is nearly C2 symmetric, apart from the ligand binding site. These 
data were generated by collaborators at GSK. 
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Figure 11. Structure-guided design of an OTI. (A) Schematic illustrating domains of type II 
topoisomerases used to determine the crystal structure of human topoisomerase IIβ covalently 
attached to DNA (green) in the presence of etoposide (orange). Domains pictured are TOPRIM 
(Top) and winged helix domain (WHD). (B) Schematic of topoisomerase II function. Protein 
protomer subunits are shown in blue and gray. T DNA, transport segment (black); G DNA, gate 
segment (green). (C,D) Detail from the crystal structure of a topoisomerase IIβ cleavage complex 
with two bound etoposide molecules (orange) stabilizing a double-stranded DNA (green) break 
(PDB code 3QX3). For clarity, in panel C, only the Cα trace of the protein subunits (blue and 
black lines) and catalytic tyrosine residues (blue and grey sticks) are shown. Continued next 
page. 
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In panel D, only the catalytic tyrosine residues that cleave the DNA are shown. The conventional 
numbering scheme used for DNA cleavage complexes formed by type II topoisomerases is 
shown. The enzyme cleaves between the -1 and the +1 on each strand. The numbering on the 
two strands in the double helix is differentiated by the presence or absence of asterisks. The 
catalytic tyrosine residues are covalently attached to the DNA at the +1 positions. (E,F) Model 
of a cleavage complex with one bound etoposide molecule stabilizing a single-stranded DNA 
break. The cleaved DNA strand is indicated by asterisks. The differences in the protein structure 
shown in E and F are the same as those in C and D. (G) Chemical (left) and modeled (right) 
structure of the etoposide core (DEPT) linked to the pyrimidine base. (H) OTI28 (orange strand) 
modeled with the modified cytosine base in the +5* position, stabilizing DNA scission at the 23-
24 site (-1 to +1) on the cleaved target strand (green). These data were generated by 
collaborators at GSK. 
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Figure 12. The alkyne moiety of the modified C or T is a rigid projection from the base. (A) 
Cytosine and thymine are compared with modified versions of the bases. Note that extra carbons 
project as a rigid rod-like group from the C5 position of the pyrimidines. The rest of the linker is 
flexible, indicated by dotted lines. (B,C) Etoposide (orange) and DNA (green) as seen in the 
cleavage complex of a 2.15 Å crystal structure of human topoisomerase IIβ (PDB code: 3QX3) 
with a molecule of etoposide. Modified bases have been superimposed on existing bases with 
the two extra carbons that protrude from the C5 position of the base shown in yellow. For clarity, 
the enzyme is not shown in B and C. (D,E) The same views as in B and C, but with the 
topoisomerase IIβ shown in cyan (space-filling model). Note that the protein clashes with the 
protruding acetylene group of the modified bases at positions -2, -1, +1 and +2, but not at 
positions +3*, +4*, +5*, and +6*. These data were generated by collaborators at GSK.  
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Chapter 3: Novel Trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones Act as 
Covalent Poisons of Human Topoisomerase IIα 
 
Introduction 
A number of topoisomerase II-targeting anticancer drugs, including amsacrine, utilize an acridine 
or related aromatic core as a scaffold. Therefore, to further explore the potential of acridine-
related compounds to act as topoisomerase II poisons, novel trifluoromethylated 9-amino-3,4-
dihydroacridin-1(2H)-one derivatives (referred to as trifluoromethylated 9-amino acridin-1(2H)-
ones) were synthesized and examined for their ability to enhance DNA cleavage mediated by 
human topoisomerase IIα. 
Results indicate that many of the trifluoromethylated 9-amino acridin-1(2H)-ones are able to 
stabilize DNA cleavage mediated by topoisomerase IIα, but that they do not do so by 
intercalating into the DNA. Initial results suggested that the compounds do not act as interfacial 
topoisomerase II poisons, as they do not inhibit enzyme-mediated DNA religation. Further 
investigation suggests that their mechanism of action is closer to that of a covalent poison, as 
their activity is severely reduced by incubation with a reducing agent, they do not stabilize 
cleavage mediated by the catalytic core of human topoisomerase IIα, and they inhibit cleavage 
by the full-length enzyme when they are incubated together prior to the addition of DNA. 
Results 
Select Substituents Allow Novel Trifluoromethylated 9-Amino Acridin-1(2H)-ones to 
Stabilize Topoisomerase IIα-mediated DNA Cleavage 
The structure of the seven trifluoromethylated 9-amino acridin-1(2H)-ones synthesized, as well 
as that of amsacrine for comparison, are shown in Figure 13. The trifluoromethyl group at C3 
was included to provide additional H-bonding groups and because the presence of fluorine 
residues often provides improved pharmacological properties, such as increased membrane 
permeability, enhanced hydrophobic binding interactions, and improved metabolic stability 
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Figure 13. Structures of amsacrine and the trifluoromethylated acridin-1(2H)-one 
derivatives used in the current study. The trifluoromethylated acridin-1(2H)-one skeleton is 
shown (top right) and the substituents at positions R1-3 (red) for compounds 1-7 are listed in the 
table. Amsacrine is shown on the bottom left. The trifluoromethylated acridin-1(2H)-one 
derivatives were synthesized by collaborators at Tennessee State University. 
  
	
Compound R1 R2 R3 
1 -H -H -NH2 
2 -H -CH3 -NH2 
3 -Cl -H -NH2 
4 -F -H -NH2 
5 -NO2 -H -NH2 
6 -Br -H -NH2 
7 -H -H -H 
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(discussed in Fadeyi et al.[216]). The syntheses of these compounds started with the 
corresponding enaminobenzonitrile[216] utilizing the generalized scheme shown in Figure 14. 
The detailed syntheses are described in Chapter 2, and physical and chemical characterizations 
of the compounds can be found in the Supplementary Data of Infante Lara et al.[197]. 
As a first step toward analyzing the effects of the trifluoromethylated acridin-1(2H)-one 
derivatives on human topoisomerase IIα, I determined the ability of these compounds to enhance 
enzyme-mediated double-stranded cleavage of negatively supercoiled DNA (Figure 15). Several 
of the trifluoromethylated acridin-1(2H)-one derivatives induced high levels of enzyme-mediated 
DNA cleavage, although none were as potent as amsacrine or etoposide. Acridine, the aromatic 
core of amsacrine, did not enhance DNA cleavage. On the basis of the cleavage data (Figure 
15), a number of structure-activity relationships among the compounds became evident. 
First, the presence of the 9-amino moiety was critical for the activity of the trifluoromethylated 
acridin-1(2H)-one derivatives. Removal of this group (converting compound 1 to compound 7) 
decreased cleavage enhancement from >8-fold to ~1.5-fold and increased the CC3 (level of 
compound required to triple baseline levels of cleavage complexes; used as a measure of 
potency because this value is within the linear range of activity for the compounds examined) 
from 155 µM to ≫1000 µM. Second, the inclusion of either a methyl group at C6 (compound 2) 
or a nitro moiety at C7 (compound 5) was deleterious and decreased both the level of DNA 
cleavage and the potency of the compounds. Third, the inclusion of halogens at C7 affected the 
activity of the compounds against topoisomerase IIα. The presence of Cl, F, or Br (compounds 
3, 4, or 6, respectively) resulted in a modest reduction (<35%) in cleavage levels (at 1000 µM 
compound) compared to compound 1. However, the chloro- and bromo-substituted compounds 
displayed an ~1.8-fold increase in potency. In contrast, the potency of the fluoro-substituted 
compound decreased ~3.4-fold. 
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Figure 14. Generalized scheme used to synthesize the trifluoromethylated acridin-1(2H)-
one derivatives used in the current study. 
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Figure 15. Effects of trifluoromethylated acridin-1(2H)-one derivatives on the DNA 
cleavage activity of human topoisomerase IIα. Results with amsacrine, etoposide, and 
acridine are shown as controls. Activity is reported as the relative increase in double-stranded 
DNA (dsDNA) cleavage as compared to reactions carried out in the absence of compounds 
(left). Error bars represent the standard deviation of at least three independent experiments. The 
table (right) provides the concentrations (CC3) of compounds 1–7, acridine, amsacrine, and 
etoposide that are required to triple levels of cleavage complexes as compared to baseline levels 
generated in the absence of the compounds. These values are used as a measure of potency. 
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Trifluoromethylated 9-Amino Acridin-1(2H)-one Derivatives Do Not Intercalate Into the 
DNA 
In some cases, enhanced interactions between topoisomerase II poisons and DNA leads to 
greater drug activity against the enzyme[113]. Therefore, the ability of the trifluoromethylated 
acridin-1(2H)-one derivatives to intercalate into DNA was assessed (Figure 16). In the 
concentration range examined, the compounds were weak intercalators at best (as determined 
by the shift in DNA topoisomer bands toward the position of negatively supercoiled DNA). 
Furthermore, there does not appear to be any correlation between the ability of the 
trifluoromethylated acridin-1(2H)-ones to intercalate and their activity against topoisomerase IIα. 
Compounds 2 and 4, for example, displayed similar DNA cleavage enhancement but very 
different intercalation patterns. Furthermore, compound 5 displayed similar intercalation to 
compound 1, but had a significantly lower potency against topoisomerase IIα. Because 
compounds 5 and 7 displayed virtually no activity against topoisomerase IIα, they were not 
subjected to further analysis. 
Trifluoromethylated 9-amino Acridin-1(2H)-one Derivatives Do Not Inhibit Enzyme-
Mediated Religation of DNA 
Clinically relevant topoisomerase II-targeting drugs, such as amsacrine and etoposide, act as 
interfacial topoisomerase II poisons[94]. Therefore, to determine whether the trifluoromethylated 
9-amino acridin-1(2H)-one derivatives act by a similar mechanism, the effects of these 
compounds on topoisomerase IIα-mediated DNA ligation were characterized (Figure 17). In 
marked contrast to amsacrine and etoposide, none of the trifluoromethylated 9- acridin-1(2H)-
ones that enhanced DNA cleavage had any significant effect on rates of ligation. The lack of 
ligation inhibition does not preclude the possibility that the trifluoromethylated 9-amino acridin-
1(2H)-one derivatives act as interfacial poisons. However, the finding suggests that these  
51 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Intercalation of trifluoromethylated acridin-1(2H)-one derivatives into 
negatively supercoiled DNA. Results of a topoisomerase I-DNA relaxation assay are shown. 
Intercalation is indicated by the shift in the position of the plasmid from that of relaxed (Rel) DNA, 
which is generated upon incubation of negatively supercoiled DNA (-SC) with topoisomerase I. 
Each lane is labeled with the number of the trifluoromethylated acridin-1(2H)-one compound that 
was tested. Three intercalators, acridine (Acr, 500 µM), ethidium bromide (EtBr, 10 µM), and 
amsacrine (Amsa, 500 µM), and a non-intercalator, etoposide (Etop, 500 µM), are shown as 
positive and negative controls, respectively. Assays that contained only -SC DNA (DNA) or -SC 
DNA and topoisomerase I with no compound (TopI) are shown. Gel is representative of three 
independent experiments. 
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Figure 17. Effects of trifluoromethylated 9-amino acridin-1(2H)-one derivatives on DNA 
ligation mediated by topoisomerase IIα. Reaction mixtures were carried out in the absence 
(No drug) or presence of 1 mM compound. Reactions that contained 50 µM amsacrine or 
etoposide are shown as positive controls. Error bars represent the standard deviation of at least 
three independent experiments. 
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compounds may instead increase levels of topoisomerase IIα-DNA cleavage complexes through 
covalent interactions with the type II enzyme. 
Trifluoromethylated 9-Amino Acridin-1(2H)-ones Display Characteristics of Covalent 
Topoisomerase II Poisons 
In order to discern which mechanism the trifluoromethylated 9-amino acridin-1(2H)-one 
derivatives utilize to alter topoisomerase II function, I first determined the effects of DTT on the 
ability of these compounds to enhance topoisomerase IIα-mediated DNA cleavage (Figure 18). 
The reducing agent dramatically decreased levels of trifluoromethylated acridin-1(2H)-one- 
induced DNA cleavage. In contrast, DTT had no effect on the activity of the interfacial poison 
amsacrine. These results strongly suggest that the trifluoromethylated 9-amino acridin-1(2H)-
one derivatives alter topoisomerase IIα-mediated DNA cleavage by acting as covalent poisons. 
Therefore, two additional experiments were carried out to confirm this mechanism. 
I assessed the effects of the trifluoromethylated 9-amino acridin-1(2H)-one derivatives on the 
catalytic core of topoisomerase IIα, a construct that lacks both the C- and N-terminal domains 
(Figure 19). Interfacial poisons such as amsacrine maintain their activity against the catalytic 
core since their activity is dependent on interactions with the enzyme and DNA at the active site, 
but the trifluoromethylated 9-amino acridin-1(2H)-one derivatives did not induce enzyme-
mediated DNA cleavage above background levels. As a final experiment, the trifluoromethylated 
9-amino acridin-1(2H)-one derivatives were incubated with topoisomerase IIα prior to the 
addition of DNA (Figure 20). All of the compounds rapidly inhibited the DNA cleavage activity of 
the enzyme. 
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Figure 18. Effects of a reducing agent on trifluoromethylated acridin-1(2H)-one- induced 
DNA cleavage mediated by topoisomerase IIα. DNA cleavage reactions were carried out in 
the presence of 1 mM trifluoromethylated 9-amino acridin-1 (2H)-one derivatives in the absence 
(green) or presence (blue) of 0.5 mM DTT. Reactions carried out in the absence of compounds 
(hTIIα) or in the presence of 50 µM amsacrine (AMSA) are shown as controls. Error bars 
represent the standard deviation of at least three independent experiments. 
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Figure 19. Effects of trifluoromethylated 9-amino acridin-1(2H)-one derivatives on DNA 
cleavage mediated by the catalytic core of topoisomerase IIα. DNA cleavage reactions using 
full-length topoisomerase IIα (green) or the catalytic core of the enzyme (blue) were carried out 
in the presence of 1 mM trifluoromethylated acridin-1(2H)-one derivatives. Reactions carried out 
in the absence of compounds (hTIIα) or in the presence of 50 µM amsacrine (AMSA) are shown 
as controls. Baseline levels of DNA cleavage mediated by the catalytic core are lower than those 
observed for the intact enzyme. Error bars represent the standard deviation of at least three 
independent experiments. 
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Figure 20. Effects of trifluoromethylated 9-amino acridin-1(2H)-one derivatives on DNA 
cleavage mediated by topoisomerase IIα when incubated with the enzyme prior to the 
addition of DNA. Cleavage reactions were initiated after topoisomerase IIα was incubated with 
1 mM derivatives for 1-5 min. The inset displays an expansion of time points between 0-1 min 
for compounds 1, 2, 3, and 6. Error bars represent the standard deviation of at least three 
independent experiments. 
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Discussion 
Taken together, the above experiments strongly suggest that the trifluoromethylated 9-amino 
acridin-1(2H)-one derivatives enhance topoisomerase IIα-mediated DNA cleavage by acting as 
covalent topoisomerase II poisons. The chemistry that underlies the adduction of topoisomerase 
IIα by the trifluoromethylated acridin-1(2H)-ones is not immediately apparent. However, given 
the essential nature of the 9-amino moiety for the activity of these compounds, it may involve 
amino-imino tautomerism or the hydrolysis of the amino group to form a more reactive species.  
It is notable that the 4’-amino-methane-sulfon-m-anisidide head group of amsacrine (which 
also includes a primary aromatic amine) displays the ability to act as a covalent topoisomerase 
II poison[113]. On the basis of comparisons to amsacrine, it will be interesting to determine 
whether the addition of a head group to the trifluoromethylated acridin-1(2H)-one derivatives at 
the 9-amino position will convert these compounds to interfacial poisons that could act as 
scaffolds for the development of novel topoisomerase II-targeting drugs. 
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Chapter 4: Coupling the Core of the Anticancer Drug Etoposide to an Oligonucleotide 
Induces Topoisomerase II-mediated Cleavage at Specific DNA Sequences 
Introduction 
Etoposide and other topoisomerase II-targeting drugs are important anticancer therapeutics. 
Unfortunately, the safe usage of these agents is limited by their indiscriminate induction of 
topoisomerase II-mediated DNA cleavage throughout the genome[217] and by a lack of 
specificity toward cancer cells[18, 21, 25, 86, 87, 106]. 
A number of cancers are associated with the presence of a driver oncogene that is generated 
by a mutation or translocation in the DNA[218-220]. The ability to rapidly sequence patients’ 
DNA affords a potential opportunity to develop new generations of topoisomerase II poisons that 
specifically target the driver mutations in cancer cells of affected individuals. This could introduce 
DNA strand breaks specifically in the oncogene or could generate cleavage complexes that act 
as roadblocks for transcription. In either case, disruption of the driver oncogene or interference 
with its transcription could potentially kill malignant cells that are dependent on the resulting 
oncoprotein. Consequently, this strategy could result in treatments that are cytotoxic toward 
cancer but display limited action against normal cells.  
 As a first step toward constraining the distribution of etoposide-induced DNA cleavage sites 
and developing sequence-specific topoisomerase II-targeting anticancer agents, the active core 
of etoposide, DEPT, was covalently coupled to oligonucleotides centered on a strong type II 
topoisomerase cleavage site in the PML gene[98, 99]. The initial sequence used for this OTI 
was identified as part of the translocation breakpoint of a patient with t-APL who had been treated 
with mitoxantrone for progressive multiple sclerosis[99]. Subsequent OTI sequences were 
derived from the observed t-APL breakpoint between PML and RARA. The proposed 
mechanism of action of OTIs can be seen in Figure 21. 
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Figure 21. Proposed mechanism of action of OTIs. (A) In a population of non-cancer cells 
with WT parental genes (1, pair of green and pair of blue lines), an OTI (short green and blue 
line with black star, middle) designed to target a translocation would be unable to stabilize DNA 
cleavage by human type II topoisomerases (yellow ovals) on the WT parental genes (2). (B) In 
a population of cancer cells whose genomes contain the targeted translocation (pair of 
green/blue lines, 1), OTIs could hybridize to the target strand on the genome (2) such that if a 
type II topoisomerase bound at that site (3), it would stabilize enzyme-mediated DNA cleavage. 
Stable cleavage presents a danger to cells, as DNA processing systems (purple shapes, orange 
line, 4) like transcription machinery could collide with the cleavage complex (5), rendering the 
topoisomerase unable to religate the cleaved DNA[93, 101]. 
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 Results indicate that OTIs can be used to direct the sites of etoposide-induced DNA cleavage 
mediated by topoisomerase IIα and topoisomerase IIβ. Furthermore, OTIs directed against the 
PML-RARA breakpoint displayed cleavage specificity for oligonucleotides with the translocation 
sequence over those with sequences matching either parental gene. Finally, OTI duplexes 
containing a single mismatch were better able to stabilize DNA cleavage by both enzymes than 
free etoposide. This finding suggests that single-nucleotide polymorphisms (SNPs) are not 
appropriate targets for OTIs. Collectively, these studies demonstrate the feasibility of using 
oligonucleotides to direct topoisomerase II-mediated DNA cleavage to specific sites in the 
genome, especially those generated by chromosomal translocations. 
Results 
Structure-based Design of OTIs that Contain the Core of Etoposide  
When cells are treated with etoposide, the drug induces topoisomerase II-mediated DNA 
cleavage at millions of sites throughout the human genome[81]. Therefore, in an effort to design 
an etoposide-based compound with specificity for cancer-associated DNA sequences, the active 
core of etoposide (DEPT) was covalently attached to a series of oligonucleotides by 
collaborators at GSK (Figures 8 and 11). DEPT was selected because it lacks the non-essential 
C4 sugar moiety of etoposide but retains a C4 hydroxyl group that can be activated for coupling 
reactions. 
 OTIs were designed to generate single-stranded, topoisomerase II-mediated cleavage on 
the strand opposite the etoposide core attachment site (Figure 11)[50]. To this end, crystal 
structures of human topoisomerase IIβ[136] and IIα[214] with two etoposide molecules and the 
bacterial Staphylococcus aureus DNA gyrase with one or two etoposide molecules[215] served 
as the basis for modeling studies (Figure 9). As a result of these studies, a linker consisting of a 
terminal alkyne moiety was attached to the C5 position of a cytosine or thymine residue and was 
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Figure 22. Models of cleavage complexes of OTI28 with human topoisomerase IIα (left) 
and IIβ (right). (A,C) Human topoisomerase IIα subunits (cyan and grey) are modeled in a 
single-stranded cleavage complex with OTI28 (orange) and target DNA (green). The target 
strand is cleaved at the 24-25 cleavage site. The crystal structure of a human topoisomerase IIα 
complex with etoposide (PDB code: 5GWK) was used in constructing the model. (B,D) Human 
topoisomerase IIβ subunits (blue and black) are modeled in a single-stranded cleavage complex 
with OTI28 (orange) and target DNA (green). The target strand is cleaved at the 24-25 cleavage 
site. The crystal structure of a human topoisomerase IIβ complex with etoposide (PDB code: 
3QX3) was used in constructing the model. Note that in these cleavage complexes, the OTI 
linker does not come close to Met762 (topoisomerase IIα)/Gln778 (topoisomerase IIβ). These 
data were generated by collaborators at GSK.  
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coupled to a 4-azide-modified DEPT via copper-catalyzed click chemistry (Figure 8). The 
modeling studies indicated that the linked DEPT was capable of intercalating into a cleaved site 
on the opposite strand (shown for OTI28 in Figures 10, 11, 12, and 22). 
An OTI Directed Against the PML Gene Enhances DNA Cleavage Mediated by Human Type 
II Topoisomerases 
As a proof of concept that a covalently attached etoposide core can function as a sequence-
specific topoisomerase II poison, an initial OTI (OTI28) was designed that utilized a DNA 
sequence spanning a strong drug-induced topoisomerase II cleavage hotspot within intron 6 of 
the PML gene (bases 1482-1489)[98]. This cleavage hotspot is also present in the t(15;17) 
translocation of a patient with APL who had been treated with mitoxantrone[99]. The interaction 
of an OTI that spanned the APL breakpoint sequence with topoisomerase II will be discussed in 
a later section. 
 The sequence of the central 30 nucleotides of the 50-base pair-oligonucleotide used for the 
initial experiments (bases 1461-1510) is shown in Figure 23A. When the unmodified 
oligonucleotide duplex (radiolabeled on its top/target strand) was treated with free etoposide in 
the presence of topoisomerase IIα, several strong DNA cleavage sites were observed (Figure 
23B). The cleavage site between bases 24-25 (1484-1485) is also a strong site for mitoxantrone 
and is believed to be the hotspot that results in ~50% of the t(15;17) translocations observed in 
patients with therapy-related APLs following treatment with mitoxantrone[87, 98, 99, 177, 180]. 
 To examine the effects of a linked drug on topoisomerase II-mediated DNA cleavage of this 
sequence, the active core of etoposide was covalently attached to cytosine 28 on the bottom 
strand (Figure 23A) through a flexible linker as described above. On the basis of modeling 
studies, the tethered drug moiety should be able to intercalate into the scissile bond between 
bases 24-25, stabilizing cleavage at that site (Figures 11 and 25A). As seen in Figure 23, this  
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Figure 23. An oligonucleotide-linked etoposide core increases topoisomerase II-mediated 
DNA cleavage. Continued next page.  
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(A) The central 30 base pairs of a double stranded 50-mer oligonucleotide sequence 
corresponding to bases 1471-1500 (top strand) of PML intron 6. The yellow box denotes the 
position of the tethered etoposide core and linker moieties on OTI28 or LIN28. Arrows indicate 
sites of DNA cleavage induced by free etoposide (blue) or OTI28 (yellow). (B) Comparison of 
DNA cleavage mediated by human topoisomerase IIα (hTIIα, left) and topoisomerase IIβ (hTIIβ, 
right) of the radiolabeled, unmodified PML top strand hybridized to an unmodified PML bottom 
strand in the presence of free etoposide or hybridized to OTI28 (bottom strand). For each gel, 
lane 1 contains the unmodified PML oligonucleotide. Lanes 2-5 contain the unmodified PML 
duplex treated with 0-500 µM free etoposide. Lanes 7 and 8 contain the unmodified PML top 
strand hybridized with OTI28. Lanes 10 and 11 contain the unmodified top strand duplexed with 
LIN28 (bottom strand oligonucleotide that contains the linker at position 28 with no attached 
etoposide core). Lanes 6, 9, and 12 contain reference (R) oligonucleotides that were 24, 23, and 
19 bases in length. Gels are representative of at least three independent experiments. (C) 
Quantification of the relative levels of DNA cleavage mediated by topoisomerase IIα (left) and 
topoisomerase IIβ (right). DNA cleavage at each site was normalized to the cleavage observed 
at site 24-25 in reactions containing unmodified duplex in the absence of etoposide (lane 2). 
Cleavage results of the unmodified duplex in the presence of 500 µM free etoposide are shown 
in blue (lane 5) and those with an unmodified top strand hybridized to OTI28 are shown in yellow 
(lane 8). Error bars represent the standard error of the mean of an average of two to five 
independent experiments. Significance was determined by paired t-tests. P-values are indicated 
by asterisks (*, p < 0.05; **, p < 0.005; ***, p < 0.0005).  
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was the case when the unmodified bottom strand was replaced with the drug-linked 
oligonucleotide (OTI28, bottom strand). Topoisomerase IIα cleaved at this position (between 
bases 24-25 on the top strand) at levels that were even higher than those observed in the 
unmodified duplex in the presence of 500 µM free etoposide. High enzyme-mediated cleavage 
was also observed one base away (between bases 23-24 on the top strand), although at slightly 
lower levels than at site 24-25. Drug insertion at this position is also supported by modeling 
studies (Figure 25B). 
 Four additional points should be noted regarding the data shown for topoisomerase IIα 
(Figure 23B,C; left): first, no DNA cleavage was observed in the absence of topoisomerase IIα 
(lane 1), indicating that the tethered etoposide core does not induce cleavage via a spontaneous 
chemical reaction. Second, OTI28 did not induce topoisomerase IIα-mediated cleavage at any 
of the other strong cleavage sites induced by free etoposide (compare lanes 8 and 5). This 
finding suggests that the specificity of the etoposide core can be constrained by its covalent 
attachment to an oligonucleotide. Third, some minor sites of topoisomerase IIα-mediated DNA 
cleavage with OTI28 were not predicted by our modeling studies (Figures 11 and 24). These 
sites were not related to the conditions utilized to anneal the OTIs to their complementary strand. 
Similar DNA cleavage patterns were observed when annealing temperatures were varied by 30 
˚C and cooling rates differed over an 8-fold range (Figure 24). These findings suggest that the 
presence of the drug may subtly alter the structure of the duplex that affects its interaction with 
topoisomerase IIα. Lastly, no enzyme-mediated DNA cleavage was observed when the bottom 
strand was replaced with an oligonucleotide that contained the linker alone (i.e., a linker with no 
attached drug moiety; lane 11). This provides strong evidence that it is the presence of the 
etoposide core rather than the linker alone on the oligonucleotide that enhances topoisomerase 
IIα-mediated DNA cleavage. 
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Figure 24. Changing annealing conditions does not change the topoisomerase IIα-
mediated DNA cleavage pattern of OTI28. A comparison of the unmodified PML top strand 
hybridized to OTI28 under different annealing conditions in the absence (-hTIIα) and presence 
(+hTIIα) of human topoisomerase IIα is shown. Annealing conditions used in the study are shown 
in lanes 3 and 4 (10-min incubation at 75 ˚C followed by slow cooling on the benchtop to 30 ºC). 
The starting temperature (S Temp) was changed over a range of 30 ºC (from 65-95 ºC, lanes 1-
8), and the cooling rate (CR) was varied by a factor of 8 (0.5-4 ºC/min, lanes 10-19) in a 
thermocycler. Lanes 9 and 20 contain reference (R) oligonucleotides that are 24, 23, and 15 
bases in length. The gel is representative of three independent experiments. 
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 Results similar to those with topoisomerase IIα also were observed with topoisomerase IIβ 
(Figure 23B,C; right). The same two strong sites of enzyme-mediated DNA cleavage were 
observed in a duplex containing OTI28. Once again, scission at both cleavage sites (24-25, 23-
24) was higher than that seen in the unmodified duplex in the presence of 500 µM free etoposide 
(compare lanes 8 and 5). However, cleavage at 23-24 was similar to that seen at 24-25. Finally,  
as seen with the α isoform, topoisomerase IIβ did not cleave a duplex with a bottom strand that 
contained a linker but no tethered etoposide core at position 28 (lane 11). 
 To further characterize the mechanism of enzyme-mediated DNA cleavage induced by the 
OTI, the effects of the tethered etoposide core on rates of DNA ligation mediated by 
topoisomerase IIα were compared to those of free etoposide on an unmodified duplex 
oligonucleotide. Similar inhibition of religation was observed for both the tethered and the 
untethered drug (Figure 26A). Thus, like free etoposide, the OTI increases levels of cleavage 
complexes by inhibiting ligation of the cut DNA. 
 In addition, cleavage complexes formed with OTI28 versus free etoposide persisted for 
similar lengths of time (Figure 26B) following 20-fold dilution of the reaction mixtures. Therefore, 
the OTI appears to stabilize cleavage complexes to a comparable extent as the free etoposide. 
These findings further suggest that the effects of tethered etoposide core within the cleavage 
complex produce similar effects to the free drug. 
 DNA lesions have the capacity to act as topoisomerase II poisons. Abasic sites are among 
the most effective DNA lesions at inducing topoisomerase II-mediated DNA cleavage[153, 154, 
157]. Thus, to provide further evidence that the effects of OTI28 were mediated by the tethered 
drug moiety as opposed to a distortion in the double helix, a new oligonucleotide was 
synthesized that replaced the cytosine-linker-etoposide core construct at position 28 with a 
tetrahydrofuran abasic site analog (AP28). DNA cleavage results are shown in Figure 27. The  
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Figure 25. Molecular models of DNA cleavage complexes formed with OTI28. Models were 
based on the crystal structure of topoisomerase IIβ[215]. (A) Cleavage between bases 24-25 is 
depicted on the target (top) strand (green). (B) Cleavage between bases 23-24 is depicted on 
the target strand (green). The bottom (OTI) strand is shown in orange. The tethered etoposide 
core is shown in yellow (carbons, yellow; nitrogen, blue; oxygen, red). A Cα trace is shown for 
the two topoisomerase II subunits (blue and black lines) in the top panels. The bottom panels 
include a semi-transparent molecular surface, illustrating that the linker does not clash with the 
protein. The sequence diagram (middle) shows the position of the tethered etoposide core on 
OTI28 (yellow box). Black arrows indicate the cleavage sites. These data were generated by 
collaborators at GSK. 
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Figure 26. OTI28 inhibits DNA ligation and stabilizes cleavage complexes similarly to free 
etoposide. (A) Enzyme-mediated ligation of DNA. (B) Persistence of cleavage complexes. For 
both A and B, cleavage results of the unmodified PML duplex in the presence of 500 µM free 
etoposide are shown in blue and those with an unmodified PML top/target strand hybridized to 
OTI28 are shown in yellow. Error bars represent the standard deviation of at least three 
independent experiments. 
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Figure 27. An oligonucleotide with an abasic site analog at position 28 generates a 
different DNA cleavage pattern than does OTI28. Lanes 1-3 contain a radiolabeled 
unmodified PML top/target strand hybridized to an unmodified PML bottom strand in the absence 
of enzyme, or in the presence of enzyme and 0-500 µM free etoposide. Lanes 4 and 5 contain 
a radiolabeled PML top strand hybridized with OTI28 (bottom strand). Lanes 6 and 7 contain a 
radiolabeled unmodified PML top strand hybridized to a bottom strand oligonucleotide containing 
an abasic site analog at position 28 (AP28). Lane 8 contains reference (R) oligonucleotides that 
are 24, 23, and 19 bases in length. The gel is representative of at least three independent 
experiments.  
hTIIα - +   +    - +   - +  R .
Etop (µM) 0 0 50
0
0 0 0 0
1     2    3    4    5   6    7    8
PML OTI28 AP28
24
23
19
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abasic site induced lower levels of cleavage than OTI28, with the major site of DNA cleavage 
(position 19-20) being five bases away from that of OTI28 (24-25) (compare lanes 7 to 5). The 
differences in the cleavage patterns obtained with AP28 and OTI28 provide additional strong 
evidence that DNA cleavage induced by OTI28 is due to the actions of the tethered etoposide 
core by type II topoisomerases and not to a distortion or lesion in the helix at the site of drug 
attachment. 
 Finally, the ability of OTI28 to induce DNA cleavage mediated by an etoposide-resistant type 
II topoisomerase was assessed. The yeast topoisomerase II H1011Y mutant[201] was used for 
these experiments for two reasons. First, target-based resistance to topoisomerase II-targeting 
drugs is generally associated with the loss of one enzyme allele or the deletion of nuclear 
localization signals[221, 222]. Consequently, point mutations that impart etoposide resistance to 
human type II topoisomerases have not been well described or characterized. Second, yeast 
topoisomerase II is highly sensitive to etoposide, and the H1011Y mutant is the only type II 
enzyme that has been shown to be etoposide resistant due to a reduced affinity for the drug[223]. 
As seen in Figure 28, yeast topoisomerase II H1011Y is ~4-fold resistant to the tethered 
etoposide core in OTI28 as compared to the wild-type enzyme. This result is consistent with the 
resistance of the mutant enzyme to free etoposide[201]. 
 Taken together, the above experiments provide strong evidence that the DNA cleavage 
induced by OTI28 is due to the presence of the tethered etoposide core. 
OTIs Enhance Topoisomerase II-mediated DNA Cleavage in a Sequence-dependent 
Manner 
As described above, the major site of topoisomerase II-mediated DNA cleavage on the top/target 
strand induced by OTI28 was located at a position two bases away and opposite the tethered 
etoposide core (site 24-25). To determine whether OTIs generate a predictable pattern of 
cleavage, the location of the tethered etoposide core was shifted to three additional locations  
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Figure 28. OTI28 induces lower levels of DNA cleavage mediated by an etoposide-
resistant mutant yeast topoisomerase II as compared to wild-type yeast topoisomerase 
II. Quantification of the relative levels of enzyme-mediated DNA cleavage at site 24-25 (indicated 
as the band labeled 24 in the inset) mediated by wild-type (yTop2WT) and H1011Y mutant 
(yTop2H1011Y) yeast topoisomerase II on an unmodified PML top strand hybridized to OTI28 
(graph: +enz, red; inset: +WT, +H1011Y). DNA cleavage is normalized to background levels of 
DNA when no enzyme is present (graph: -enz, blue; inset: -WT, -H1011Y). Error bars represent 
the standard deviation of three independent experiments. Significance was determined by a 
paired t-test. P-values are indicated by asterisks (***, p < 0.0005). 
 
 
  
73 
 
 
along the sequence of the bottom oligonucleotide: positions 29 (OTI29), 33 (OTI33), and 23 
(OTI23) (Figure 29A). These locations were selected to determine if it was possible to move the 
major site of DNA cleavage to the second-strongest site of scission induced by OTI28 (site 23-
24), to the site of secondary DNA cleavage induced when free etoposide was added to an 
unmodified duplex (site 19-20), and to a site that was not cleaved in the presence of free 
etoposide (site 29-30), respectively. 
 In all three cases, strong topoisomerase IIα-mediated DNA cleavage induced by the new 
OTIs was observed two bases away opposite the drug location at the predicted sites described 
above (Figure 29B; left). As with OTI28, some of the new OTIs also induced DNA scission at 
sites that were not predicted by our modeling studies (Figures 11 and 25). However, these sites 
were all in the vicinity of the predicted sites of cleavage. Similar sites of DNA cleavage were 
obtained with these OTIs and topoisomerase IIβ (Figure 29B; right). 
 Two important conclusions can be drawn from these studies. First, OTIs can be used to 
induce DNA cleavage, at least in part, in a predictable manner. Second, sites of cleavage can 
be moved to sequences not normally associated with the actions of free etoposide (Figures 23 
and 29). Thus, the use of OTIs is not restricted to pre-existing etoposide-induced sites of 
cleavage, implying that it may be possible to design OTIs against almost any patient sequence 
associated with a cancer mutation or chromosomal breakpoint. 
OTIs Can Be Directed Against a t(15;17) Translocation Breakpoint Seen in a Patient with 
t-APL 
One of the goals in characterizing OTIs is to determine if it would be possible to target them to 
cancer-specific sequences present in malignant cells. Therefore, having established the proof 
of principle that OTIs can be used to direct the location of etoposide-induced topoisomerase II-
mediated DNA cleavage, an OTI was designed against a t(15;17) chromosomal translocation 
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Figure 29. Moving the position of the linked etoposide core on the bottom strand OTI 
sequence alters the topoisomerase II-mediated cleavage pattern of the top strand. (A) 
Sequences of the top/target and bottom PML strands. The different-colored boxes indicate the 
position of the tethered etoposide core in each OTI (bottom strand), including OTI28 (yellow), 
OTI29 (orange), OTI33 (green), and OTI23 (purple). Arrows indicate the cleavage sites induced 
by each OTI (shown by corresponding colors). Blue arrows indicate cleavage sites induced by 
free etoposide. The size of the arrows is indicative of the relative strength of cleavage. T and B 
(first column) indicate top and bottom strands, respectively. (B) Comparison of DNA cleavage 
mediated by human topoisomerase IIα (hTIIα, left) and topoisomerase IIβ (hTIIβ, right) of the 
radiolabeled, unmodified PML top strand hybridized to an unmodified PML bottom strand in the 
presence of 0-500 µM free etoposide (lanes 2-3) or hybridized to the bottom strands OTI28 
(lanes 5-6), OTI29 (lanes 8-9), OTI33 (lanes 11-12), or OTI23 (lanes 14-15). For each gel, lane 
1 contains an unmodified PML duplex. Reference (R) oligonucleotides are 24, 23, 20, and 19 
bases long. Gels are representative of at least three independent experiments. 
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(breakpoint at 1484-1485 in PML and 12034-12035 in RARA) in a patient with t-APL (Figure 
30A)[99]. This sequence was chosen because it encompasses the site of cleavage in the PML 
gene induced by OTI28 (Figure 23). Initial studies with the translocation sequence utilized a 50-
base pair oligonucleotide that was comprised of bases 1461-1488 of intron 6 of PML (Figure 
30A; green) and 12039-12060 of intron 2 of RARA (Figure 30A; orange). 
 First, the unmodified breakpoint oligonucleotide duplex was treated with free etoposide (0-
500 µM) in the presence of topoisomerase IIα, and several cleavage sites were observed (Figure 
30B,C; left). The strongest of these sites were observed at positions 24-25, 25-26, and 19-20 on 
the top strand (lane 5), in order of decreasing strength of cleavage. 
 Second, the unmodified target strand was hybridized with a complementary 50-base OTI in 
which the tethered etoposide core was located at the equivalent position in the PML gene as 
OTI29 (Figure 30A). As predicted, this OTI induced strong cleavage at position 23-24 (lane 8), 
at a site two bases away and opposite the tethered drug. Strong cleavage was also observed at 
sites 20-21 and 24-25 (lane 8). 
 Human type II topoisomerases display a DNA length-dependence for scission. The enzyme 
cleaves a 50-mer duplex oligonucleotide considerably better than it does a 40-mer, and little 
cleavage is seen with oligonucleotides shorter than a 30-mer[92]. However, when one of the two 
strands is maintained at a 50-base length, levels of enzyme-mediated DNA cleavage remain 
relatively high until the length of the complementary strand is reduced to ~20 bases[92]. 
Therefore, to see if shorter OTIs could still be used to induce high levels of topoisomerase IIα-
mediated DNA cleavage in the translocation sequence, I tested a 30-mer version of the 
breakpoint OTI in which 10 bases were removed from each terminus (Figure 30A). High levels 
of cleavage were maintained at sites 23-24 and 19-20; however, cleavage disappeared from site 
24-25 (Figure 30B,C; lane 12). As predicted, when the breakpoint OTI was further reduced in 
length to a 20-mer version, DNA cleavage levels dropped precipitously (Figure 30B,C; lane 14). 
76 
 
 
 
Figure 30. OTIs designed against a patient-observed PML-RARA translocation increase 
DNA cleavage mediated by human type II topoisomerases. (A) Sequences of the top and 
bottom strands of each PML-RARA duplex are shown. The blue portion corresponds to the 
segment derived from the PML gene, and the orange portion corresponds to the segment 
derived from the RARA gene. Continued next page. 
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The yellow box indicates the position of the tethered etoposide core on each OTI (bottom strand). 
The OTIs were 50, 30, or 20 bases in length (black lines below the diagram). Arrows indicate 
sites of DNA cleavage induced by free etoposide (blue) and the translocation OTIs (yellow). (B) 
Comparison of DNA cleavage mediated by human topoisomerase IIα (hTIIα, left) and 
topoisomerase IIβ (hTIIβ, right) of the radiolabeled, unmodified PML-RARA top/target strand 
hybridized to an unmodified PML-RARA bottom strand in the presence of free etoposide or of 
the radiolabeled PML-RARA top strand hybridized to a 50-mer, 30-mer, or 20-mer PML-RARA 
OTI bottom strand. Lanes 1-5 contain the unmodified PML-RARA duplex in the absence of 
enzyme, or in the presence of enzyme and 0-500 µM free etoposide. Lanes 7 and 8 contain the 
unmodified PML-RARA top strand hybridized with the 50-mer OTI. Lanes 10 and 11 contain the 
unmodified top strand hybridized with the 30-mer OTI. Lanes 13 and 14 contain the unmodified 
top strand hybridized with the 20-mer OTI. Lanes 6, 10, 13, and 15 contain reference (R) 
oligonucleotides 24, 23, 20, and 19 bases in length. Gels are representative of at least three 
independent experiments. (C) Quantification of the relative levels of enzyme-mediated DNA 
cleavage. DNA cleavage at each site is normalized to the cleavage observed at site 24-25 in 
reactions containing an unmodified duplex in the absence of etoposide (lane 2). Results with 
unmodified PML-RARA duplex in the presence of 500 µM free etoposide (blue) or with 
unmodified top strand hybridized with 50-mer OTI (yellow). 30-mer OTI (orange), or 20-mer OTI 
(green) bottom strand are shown. Error bars represent the standard deviation of at least three 
independent experiments. Significance was determined by paired t-tests. P-values are indicated 
by asterisks (*, p < 0.05; **, p < 0.005; ***, p < 0.0005). 
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In all respects, results obtained with topoisomerase IIβ and the chromosomal translocation 
model oligonucleotides (with either a free or a tethered etoposide core) were similar to those 
obtained with topoisomerase IIα (Figure 30B,C; right). 
 Finally, to determine whether the breakpoint OTIs displayed specificity for the translocation 
over the parental PML and RARA sequences, the 50-mer, 30-mer, and 20-mer breakpoint OTIs 
were hybridized to 50-mer top strands of each parental gene. Very low levels of DNA cleavage 
were generated by either topoisomerase IIα (Figure 31A) or topoisomerase IIβ (Figure 31B) in 
the PML oligonucleotide (lanes 8, 10, and 12) and no cleavage was observed in the RARA 
oligonucleotide with any of the breakpoint OTIs (lanes 18, 20, 22). This finding suggests that 
OTIs could potentially be directed to cancer-specific breakpoints without generating significant 
levels of DNA cleavage in the wild-type parental sequences. 
OTIs Induce DNA Cleavage Mediated by Human Type II Topoisomerases on Duplexes 
Containing a Mismatch 
Cancers can arise from a variety of mechanisms and are not limited to chromosomal 
translocations[224-229]. Therefore, I sought to determine if OTIs could be used to target SNPs 
such as might be present in a driver oncogene. In such a situation, OTIs could be used to induce 
enzyme-mediated DNA cleavage on the SNP-containing sequence (wherein the OTI would form 
a fully complementary duplex with its target sequence on the cancer genome) but not on the WT 
parental sequence (which would contain a one-base mismatch when hybridized to the OTI). To 
test this possibility, I designed six new oligonucleotides (C19G, G23A, C24G, C24A, C24T, and 
C25G) that shared the sequence of the WT PML top strand but differed by a single-base. These 
“mismatch oligonucleotides” were hybridized to WT PML or OTI bottom strands. To investigate 
the full potential of OTIs in targeting SNPs, I designed the mismatch oligonucleotides to generate 
the greatest amount of disruption in the double helix in the hopes of maximizing the interference 
with topoisomerase IIα and IIβ. This is representative of the best-case scenario in which an OTI 
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Figure 31. OTIs that incorporate an APL patient-derived PML-RARA translocation 
sequence do not increase DNA cleavage mediated by human type II topoisomerases 
when they are hybridized with the parental PML or RARA sequences. Continued next page. 
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Comparison of DNA cleavage mediated by human topoisomerase IIα (hTIIα) (A) and 
topoisomerase IIβ (hTIIβ) (B) of the radiolabeled top strand of an unmodified PML-RARA duplex 
in the presence of free etoposide, a radiolabeled, unmodified PML or RARA top strand hybridized 
to a PML-RARA bottom strand in the presence of free etoposide, or a radiolabeled, unmodified 
PML or RARA top strand hybridized to a 50-mer OTI, a 30-mer OTI, or a 20-mer PML-RARA 
OTI bottom strand. For each gel, lanes 1-3 contain unmodified PML-RARA top/target strand 
hybridized to the unmodified 50-mer PML-RARA bottom strand, in the absence of enzyme, or in 
the presence of enzyme and 0-500 µM etoposide. Lanes 4-6 contain unmodified parental PML 
top/target strand hybridized to the unmodified 50-mer PML-RARA bottom strand, in the absence 
of enzyme, or in the presence of enzyme and 0-500 µM etoposide. Lanes 7-12 contain the 
unmodified parental PML top strand hybridized to the 50-mer, 30-mer, or 20-mer PML-RARA 
OTI bottom strand in the absence or presence of enzyme. Lanes 14-16 contain unmodified 
parental RARA top strand hybridized to the 50-mer PML-RARA bottom strand, in the absence 
of enzyme, or in the presence of enzyme and 0-500 µM etoposide. Lanes 17-22 contain the 
unmodified parental RARA top strand hybridized to the 50-mer, 30-mer, or 20-mer PML-RARA 
OTI bottom strand in the absence or presence of enzyme. Lanes 13 and 23 contain a 
combination of reference (R) oligonucleotides 24, 23, 20, and 19 bases in length. Gels are 
representative of at least three independent experiments. 
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targeting a SNP is subjected to the highest possible amount of disruption when attempting to 
bind/stabilize enzyme-mediated cleavage on the WT sequence. The locations of the mismatches 
were selected on the basis of their proximity to the observed cleavage sites at 19-20, 23-24, and 
24-25 (Figure 23), and the mismatched base in each one was designed to generate the highest 
amount of DNA breathing[204]. In one instance, all three possible base mutations were 
generated for a position (C24G, C24A, C24T). 
 In addition to probing the potential use of OTIs against SNPs, generating mismatch 
oligonucleotide duplexes allowed me to explore whether or not changing the bases that flank 
scissile bonds affects the ability of topoisomerase IIα to cleave the DNA within the context of the 
OTI-attached DEPT. Human type II topoisomerases interact with DNA in a sequence-dependent 
manner[149, 230], but the sequence requirement changes based on the presence or absence 
of a topoisomerase II poison (Table 2)[149, 231-235]. For example, human topoisomerase IIα 
has a strong preference for sequences with a C at the -1 position (the base that is 5’ of the 
scissile bond) in the absence of drug and when incubated with etoposide[230], but displays a 
preference for A when incubated with doxorubicin[231] or a preference for T when incubated 
with amsacrine[232, 233]. It is important to note that although topoisomerases have sequence 
preferences, they do not necessarily cut at every site that displays the preferred sequences. 
Furthermore, type II topoisomerases display little or no DNA cleavage in the absence or 
presence of drug when there are mismatches at the -1, -2, -3, and -4 positions relative to a 
scissile bond, but mismatches at +1 or +2 may increase cleavage[236]. As OTIs contain a 
covalently linked topoisomerase II poison, they allow for the exploration of whether the sequence 
requirement for etoposide can be bypassed by having the drug “hardwired” into the system, and 
whether mismatches can affect the ability of the enzymes to cleave OTI-containing duplexes. 
 To examine these issues, I incubated topoisomerase IIα and IIβ with unmodified duplexes 
containing a radiolabeled mismatch oligonucleotide top strand and a WT PML bottom strand in 
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Enzyme/
drug 
Nucleotide position 
-5 -4 -3 -2 -1 +1 +2 +3 +4 +5 +6 +7 +8 +9 
hTIIα No A No T A, no C - 
C, no 
A - - - - No T - 
T, no 
G 
C, no 
A - 
hTIIβ - - No C G - T - - - No T - T, no G C - 
Etop.     C, (T)          
Doxo.    T A          
Mitox.     C, T  G        
Amsa     T A         
 
Table 2. Sequence preferences for human topoisomerase IIα and topoisomerase IIβ in the 
absence and presence of topoisomerase II poisons. Nucleotides in parentheses indicate a 
secondary preference. Nucleotide position is relative to a scissile bond, where (-) indicates a 
position 5’ bond and (+) indicates a position 3’ to the bond. Hyphens indicate no preference. 
Gray shading indicates no data are available[149, 230-235]. hTIIα, human topoisomerase IIα; 
hTIIβ, human topoisomerase IIβ; Etop, etoposide; Doxo, doxorubicin; Mitox., mitoxantrone; 
Amsa, amsacrine. 
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the presence of 0-500 µM etoposide (Figure 32); each duplex is heretofore referred to by the 
name of its top strand. Compared to the WT duplex with 500 µM etoposide (lanes 1-3, both gels), 
cleavage of the mismatch-containing oligonucleotides dropped precipitously at most sites. 
Notice, for example, the low levels of cleavage observed on C24G (lanes 11, top gel, and 15, 
bottom gel) and C24A (lanes 23, top gel, and 19, bottom gel) when incubated with either enzyme 
and free etoposide. These data suggest that a mismatch proximal to a cleavage site precludes 
the formation of the proper ternary drug-enzyme-DNA complex that is necessary for stabilization 
of cleavage by the topoisomerase II poisons. There were, however, clear increases in drug-
induced enzyme-mediated cleavage at sites distal to the mismatch. These locations were site 
24-25 on C19G (lanes 19, top gel, and 7, bottom gel) and site 19-20 on G23A (lanes 7, top gel, 
and 11) and on C24T (lanes 27, top gel, and 23, bottom gel). It is not immediately apparent why 
cleavage increases distally to the mismatches, but it is possible that local changes in structure 
are translated down the double helix such that the distal cleavage sites facilitate the formation 
of the ternary complex[204]. Overall levels of cleavage were lower in reactions containing 
topoisomerase IIα versus topoisomerase IIβ. 
Following these initial experiments, I tested whether OTIs could affect the amount of 
cleavage observable at the three primary cleavage sites observed in Figure 23. Topoisomerase 
IIα- and IIβ-mediated cleavage at 24-25 was monitored on duplexes containing either WT PML, 
C24G, C24A, C24T, or C25G as top strand and WT PML, OTI28, or OTI29 as the bottom strand 
(Figure 33). The results in Figure 33B suggest that mismatches 5’ to the cleavage site (C24G, 
C24A, C24T) tend to maintain lower levels of cleavage mediated by both enzymes compared to 
mismatches 3’ to the cleavage site (C25G). Similar results were observed at site 23-24 (Figure 
34), although the effect was less pronounced. Cleavage 5’ to site 19-20 (Figure 35) was also 
lower in C19G/OTI33 duplexes. Generally, OTIs induced higher levels of enzyme-mediated 
cleavage (yellow and orange bars, Figures 33 and 34) on duplexes containing mismatches  
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Figure 32. Duplexes containing a single mismatch did not generally stabilize cleavage by 
topoisomerase IIα or IIβ in the presence of free etoposide. Continued next page. 
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Comparison of DNA cleavage mediated by human topoisomerase IIα (hTIIα) (A) and 
topoisomerase IIβ (hTIIβ) (B) of the radiolabeled PML or radiolabeled mismatch oligonucleotide 
top strand hybridized to a PML bottom strand in the presence of free etoposide (Etop). For each 
gel, lanes 1-3 contain a PML top strand hybridized to a PML bottom strand, in the absence of 
enzyme, or in the presence of enzyme and 0-500 µM etoposide. Each gel also shows the 
cleavage products of reactions containing a PML bottom strand annealed to a radiolabeled 
C19G (lanes 17-19 [A] and 5-7 [B]), G23A (lanes 5-7 [A] and 9-11 [B]), C24G (lanes 9-11 [A] 
and13-15 [B]), C24A (lanes 21-23 [A] and 13-15 [B]), C24T (lanes 25-27 [A] and 21-23 [B]), or 
C25G (lanes 13-15 [A] and 24-26 [B]) top strand in the absence of enzyme or in the presence 
of 0-500 µM etoposide. Lanes 4, 8, 12, and 16 of (A) contain a combination of reference (R) 
oligonucleotides 29, 27, 24, 23, 20, 19, and 15 bases in length. Lanes 20, 24, and 28 of (A) 
contain a combination of reference oligonucleotides 29, 27, 24, 23, 20, and 19 bases in length. 
Lanes 4, 8, 12, 16, 20, and 27 of (B) contain a combination of reference oligonucleotides 24, 23, 
20, and 19 bases in length. Gels are representative of at least three independent experiments. 
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compared to similar duplexes in the presence of free etoposide (blue bars, Figures 33 and 34). 
Cleavage on duplexes containing C24T tended to be higher than the cleavage on duplexes 
containing the other two mismatch oligonucleotides, indicating that the identity of the specific 
mismatch plays a role in whether or not topoisomerase IIα or IIβ can stably cleave at that site or 
not. These results are unexpected in that G:A mismatches (as in C24A) are reported to induce 
less DNA breathing than the other G:X mismatches used here[204], but the levels of cleavage 
on C24A were lower than the levels on cleavage on C24T. It is clear that the convergence of 
mismatches, OTIs, and type II topoisomerases create a complicated interaction that warrants 
further study. 
 The results observed in Figures 33, 34, and 35 indicate, first and foremost, that OTIs can 
induce cleavage by both topoisomerase IIα and IIβ even when their cognate sequences contain 
a mismatch. This suggests that OTIs are not currently optimized to target SNPs. These results 
are promising, however, when considering that cancerous tumors can display startling genetic 
heterogeneity[225] and that can evolve over time. If a patient were to receive an OTI to target a 
particular sequence, these results indicate that it might retain its effectiveness against the target 
sequence and against any variations that might arise through mutations or that might exist in a 
heterogeneous population of cancer cells. 
Discussion 
Etoposide and other topoisomerase II-targeting drugs are important therapeutics for the 
treatment of cancer[8, 18, 86, 87, 106, 237]. Unfortunately, the induction of topoisomerase II-
mediated DNA cleavage throughout the genome, coupled with the lack of specificity toward 
cancer cells, limits the safe usage of these drugs. Among the most insidious of toxicities related 
with treatment with topoisomerase II poisons is the development of secondary leukemias[87, 
162, 180, 238]. Indeed, as many as 3% of patients treated with etoposide or doxorubicin develop 
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t-AMLs with translocations at chromosomal band 11q23[163, 239] or treated with mitoxantrone 
develop t-APLs with t(15;17) translocations[98, 240]. 
 One approach to providing anticancer agents with reduced toxicities is to develop drugs that 
specifically inhibit the activity of driver oncoproteins. An example is imatinib, which targets the 
TK domain of the bcr-abl fusion tyrosine kinase that is generated by the chromosomal 
translocation in chronic myelogenous leukemia[241]. An alternative approach would be to target 
the chromosomal translocation itself by specifically cleaving the DNA in the vicinity of the 
translocation site. This could lead to disruption of the oncogene or interference with its 
transcription. If either occurred, it ultimately could rob the cell of the oncoprotein that drives 
malignant tumor growth. Potentially, a cocktail of OTIs that target a variety of sites on a cancer 
genome (at oncogene super-enhancers[242] or the genomic loci of long non-coding RNA[243], 
for example) or even within a single oncogene could be generated, thus compounding the 
negative effect of the transcriptional interference. 
 Previous attempts to impart specificity to topoisomerase-targeting drugs were based on the 
attachment of either camptothecin[244] or etoposide derivatives[245] to the ends of triplex-
forming oligonucleotides. The attached camptothecin induced topoisomerase I-mediated DNA 
scission at sites that were consistent with the location of the linked drug[244]. However, cleavage 
appeared to be constrained to pre-existing cleavage sites[244]. In contrast, the attachment of 
etoposide to the end of a triplex-forming oligonucleotide induced DNA cleavage at locations that 
were approximately 10 base pairs away from sites that could have come into physical contact 
with the drug based on the length of the drug and linkers employed[245]. Thus, the basis for 
etoposide-induced DNA cleavage that resulted from the triplex-forming oligonucleotides could 
not be determined[245].  
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Figure 33. Cleavage patterns at 24-25 on duplexes containing a mismatch at a position 
flanking the cleavage site change compared to cleavage on duplexes containing no 
mismatch. Continued next page. 
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(A) Central 18 base pairs of the mismatch oligonucleotide duplexes used in these experiments. 
The changed base is indicated in red. X is a G, A, or T. Colored boxes indicate the position of 
the attached etoposide depending on whether OTI28 (yellow) or OTI29 (orange) was used. The 
WT sequence used can be found in Figure. (B) Quantification of the relative levels of DNA 
cleavage mediated by topoisomerase IIα (top) and topoisomerase IIβ (bottom). DNA cleavage 
at each site was normalized to the cleavage observed at site 24-25 in reactions containing 
unmodified duplex in the presence of 500 µM etoposide. WT PML or mismatch top strands were 
utilized in all reactions as indicated. Cleavage of duplexes where the bottom strand was a WT 
PML bottom strand in the presence of 500 µM free etoposide are shown in blue, where the 
bottom strand was OTI28 are shown in yellow, and where the bottom strand was OTI29 are 
shown in orange. Error bars represent the standard deviation of at least two independent 
experiments. 
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Figure 34. Cleavage patterns at 23-24 on duplexes containing a mismatch at a position 
flanking the cleavage site change compared to cleavage on duplexes containing no 
mismatch. Continued next page. 
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(A) Central 18 base pairs of the mismatch oligonucleotide duplexes used in these experiments. 
The changed base is indicated in red. X is a G, A, or T. Colored boxes indicate the position of 
the attached etoposide depending on whether OTI28 (yellow) or OTI29 (orange) was used. The 
WT sequence used can be found in Figure. (B) Quantification of the relative levels of DNA 
cleavage mediated by topoisomerase IIα (top) and topoisomerase IIβ (bottom). DNA cleavage 
at each site was normalized to the cleavage observed at site 24-25 in reactions containing 
unmodified duplex in the presence of 500 µM etoposide. WT PML or mismatch top strands were 
utilized in all reactions as indicated. Cleavage of duplexes where the bottom strand was a WT 
PML bottom strand in the presence of 500 µM free etoposide are shown in blue, where the 
bottom strand was OTI28 are shown in yellow, and where the bottom strand was OTI29 are 
shown in orange. Error bars represent the standard deviation of at least three independent 
experiments. 
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Figure 35. Cleavage patterns at 19-20 on duplexes containing a mismatch at a position 5’ 
to the cleavage site decreases compared to cleavage on duplexes containing no 
mismatch. (A) Central 18 base pairs of the mismatch oligonucleotide duplexes used in these 
experiments. The changed base is indicated in red. A green box indicates the position of the 
attached etoposide when OTI33 is used as a bottom strand. The WT sequence used can be 
found in Figure. (B) Quantification of the relative levels of DNA cleavage mediated by 
topoisomerase IIα (left) and topoisomerase IIβ (right). DNA cleavage at each site was normalized 
to the cleavage observed at site 24-25 in reactions containing unmodified duplex in the presence 
of 500 µM etoposide. WT PML or mismatch top strands were utilized in all reactions as indicated. 
Cleavage of duplexes where the bottom strand was a WT PML bottom strand in the presence of 
500 µM free etoposide are shown in blue and reactions where the bottom strand was OTI33 are 
shown in green. Error bars represent the standard deviation of at least two independent 
experiments. 
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 Although the present study also utilized drug-linked oligonucleotides to enhance the 
specificity of etoposide-induced DNA cleavage, the approach was to design sequences that 
would form duplex (rather than triplex) structures at the proposed sites of cleavage. To this end, 
a series of oligonucleotides that contained a linked etoposide core (OTIs) was synthesized using 
a copper-catalyzed click chemistry scheme. OTIs were designed to take advantage of the 
following: 1. Etoposide acts by a known mechanism in which it enhances DNA cleavage 
mediated by type II topoisomerases[18, 49, 106]. 2. The type II enzymes are validated targets 
for chemotherapeutic agents[18, 86, 95, 106]. 3. Levels of type II topoisomerases are generally 
higher in malignant cells, which generates higher levels of DNA strand breaks in treated 
cells[246, 247]. 4. Cancer cells often have high metabolic rates, which results in more replication 
and transcription complexes that convert topoisomerase II-DNA cleavage complexes into 
permanent double-strand breaks[18, 81, 86]. 
 Results indicate that the tethered etoposide core in OTIs acts against type II topoisomerases 
in a manner similar to that of the free drug, but with a specificity (at least for the major sites of 
cleavage) that is tied to its site of linkage on the oligonucleotide. Furthermore, the linked drug 
can induce enzyme-mediated DNA cleavage at sites of action of the free drug or at sites at which 
free drug does not act. This finding suggests that it might be possible to develop OTIs against a 
broad range of translocation-related sequences. Results further suggest that OTIs can be 
designed to have high activity against cancer-related translocations but display limited activity 
against the parental genes. 
 It is notable that in some cases, minor cleavage is observed at positions that were not 
predicted from modeling studies (Figures 10, 11, 22, and 25). Although the basis for cleavage 
at these minor sites is not obvious, it is possible that they are induced by distortions in the 
oligonucleotide caused by the presence of the OTI. Alternatively, an OTI attached to the 
transport helix could act in trans to induce cleavage within the gate helix (Figure 11A). However, 
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this seems unlikely, as cleavage patterns for these minor sites do not coincide with those 
observed in the presence of free etoposide (compare Figure 23 to Figure 29). 
 In contrast to their ability to target translocations over parental sequences, OTIs are less able 
to discern between parental sequences and sequences containing single mismatches, 
suggesting that they are not currently optimized to target SNPs. However, it does appear that 
OTIs can retain effectiveness against their target sequences even in the presence of 
mismatches, which could either arise as a result of mutation in a cancer cell lineage or could 
simply be present as variations in a heterogeneous population of cancer cells[225].  
 In order for OTIs to function in cells and block the expression of driver oncogenes, they would 
have to hybridize to their target sequence. It is envisioned that this could potentially take place 
when the two strands of the double helix are separated during replication or transcription (Figure 
21). In vitro experiments suggest that single-stranded oligonucleotides as short as 24-mers can 
invade the double helix and form a D-loop[248]. Alternatively, invasion can be greatly enhanced 
by the presence of recombination proteins[249, 250]. 
 The development of oligonucleotide-based therapeutics has been challenging[251]. 
However, improved chemistry and targeted delivery systems, together with the recent FDA 
approval of new RNA therapeutics[251], hold promise for the potential development of 
oligonucleotide-based agents. Modifying the chemical makeup of OTIs from deoxyribonucleic 
acids to a different backbone, such as peptide nucleic acids[252], could enhance their affinity for 
the cognate genomic sequence, possibly enhancing their efficiency and allowing for their use 
against SNPs.
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Chapter 5: Conclusions and Future Directions 
 
The material discussed in this dissertation aims to address the issue of target specificity in 
chemotherapeutic topoisomerase II poisons. Although this class of topoisomerase II-targeting 
drugs is efficacious against cancer cells for a variety of reasons (see Chapter 1), it also induces 
undesirable side effects[102]. 
First, considerable circumstantial evidence indicates that topoisomerase IIβ is the primary 
isoform associated with the toxic side effects associated with treatment with topoisomerase II 
poisons, such as leukemogenesis and cardiotoxicity[63, 86, 87, 184, 253-257]. Developing 
compounds that are more specific to the α isoform compared to the β isoform could help reduce 
topoisomerase II poison-related toxicities[258, 259]. However, given the high structural similarity 
of the isoforms, this task has proven to be difficult, and no truly isoform-specific compounds have 
been developed to date[18, 259]. Unfortunately, many of the compounds that have preferences 
for one isoform or the other tend to induce higher-fold increases in DNA cleavage mediated by 
topoisomerase IIβ rather than IIα[127, 129, 148, 190]. Given the problems associated with 
current topoisomerase II poisons, the exploration of new drug scaffolds could help identify new 
compounds that have the potential to be stronger topoisomerase II poisons than the currently 
used drugs and to be more specific for topoisomerase IIα. 
The work in Chapter 3 explored the use of trifluoromethylated 9-amino-3,4-dihydroacridin-
1(2H)-one derivatives (Figure 13) as topoisomerase II poisons. Initial experiments indicated that 
five of the seven derivatives tested were topoisomerase IIα poisons, but they were not nearly as 
potent as etoposide or amsacrine (Figure 15). By their CC3 measures, the most potent derivative 
(compound 3) was 10 times less potent than amsacrine and about 2.6 times less potent than 
etoposide (Figure 15). As enhanced interactions with DNA can lead to greater drug activity 
against type II topoisomerases[113], the compounds were tested for their ability to intercalate 
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with DNA (Figure 16). Some of the derivatives were weak intercalators at best (such as 
compound 3), and a couple did not appear to intercalate into the DNA at all. Additional testing 
indicated that the trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-one derivatives carried 
out their topoisomerase II-poisoning activity through a covalent poison mechanism (Table 1). 
This was suggested by a lack of inhibition of topoisomerase IIα-mediated religation (Figure 17), 
by the sharp reduction of compound activity after incubation with DTT (Figure 18), by a lack of 
activity against the catalytic core of the enzyme (Figure 19), and by the inhibition of enzyme-
mediated DNA cleavage when the compounds were incubated with the enzyme prior to the 
addition of DNA (Figure 20). 
Although many dietary poisons that are associated with chemoprevention are covalent 
poisons of topoisomerase II, all of the clinically relevant poisons act in a non-covalent manner 
by preventing religation of the DNA at the DNA-enzyme interface[94, 260]. Covalent 
topoisomerase poisons act by adducting (primarily to cysteines) their target enzyme, but they 
have the potential to interfere with the function of a plethora of other proteins. Thus, the current 
structures of the trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-one derivatives explored 
in this dissertation are not promising for the development of new clinical compounds. It is worth 
noting that the 4’-amino-methane-sulfon-m-anisidide head group of amsacrine acts as a covalent 
topoisomerase II poison, yet the intact amsacrine molecule acts as an interfacial poison[113]. 
Coupling the trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-one derivatives to a 
headgroup could change the nature of their interaction with DNA and with the enzyme. No tests 
were carried out with topoisomerase IIβ, but given the relatively high concentration of the 
derivatives required to enhance cleavage by topoisomerase IIα compared to etoposide and 
amsacrine, such testing is likely to be superfluous without modification of the skeleton of the 
trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones. Future work in collaboration with the 
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laboratory of Dr. Cosmas Okoro at Tennessee State University intends to explore related 
compounds (with and without headgroups) against human type II topoisomerases. 
A second source of topoisomerase II poison-related side effects is the ubiquitous nature of 
type II topoisomerases throughout the body[59, 87, 162, 181, 185]. Reduction of those side 
effects would result from better drug targeting of cancer cells. Current approaches include the 
use of nanoparticles[192-194], drug-polymer conjugates[189-191], drug-loaded hydrogels[195], 
receptor-based targeting[194], and antibody-drug conjugates[196] among others. Chapter 4 
takes a DNA-targeting approach, as it explores the use of oligonucleotide-drug conjugates 
(OTIs) that are specific to DNA sequences present in cancer cells. The decreasing costs of 
genome sequencing[261, 262] suggest that OTIs use could be highly individualized. 
OTIs are designed such that their oligonucleotide portion is complementary to cancer-specific 
DNA sequences. It is envisioned that OTIs, as currently designed, could bind to their 
complementary sequence when the double helix is opened during transcription or replication 
(Figure 21). Once bound to their target sequence, the linked topoisomerase II poisons could 
induce the formation of topoisomerase II cleavage complexes at that site that would then 
interfere with proper replication and transcription at that locus. As OTIs would be designed to 
target cancer-specific sequences, their effect on non-cancerous cells is expected to be minimal. 
The current design of OTIs was informed by several factors. The chosen topoisomerase II 
poison was etoposide given that it has historically been well studied[50, 106, 115, 119, 121, 124, 
223], and therefore any observed effects of the OTIs against type II topoisomerases could be 
interpreted within the context of previous knowledge. As the active core of etoposide, DEPT, 
shows similar levels of activity against topoisomerase II compared to the parent compound[123, 
124], it was utilized in the synthesis of the OTIs. DEPT lacks the sugar moiety at C4, which 
allowed for the activation of the C4 hydroxyl group for coupling reactions. 
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Another factor affecting the design of the OTIs was the length of the linker that joined the 
DEPT to the oligonucleotide (Figure 8). Computational simulations with OTIs of different linker 
lengths (data not shown) indicated that the linker needed to be long enough to allow the DEPT 
to curve back into the DNA, as shorter linkers placed the DEPT outside of the bounds of the 
double helix (data not shown). Based on the simulations, the selected linker length allowed the 
DEPT to interact with the DNA on the opposing strand (Figures 11, 12, 22, and 25). 
Finally, the sequence chosen for the initial OTIs was that of intron 6 of the PML gene, which 
contains a strong drug-induced topoisomerase II cleavage hotspot[84, 87, 98, 99]. Subsequent 
OTIs were synthesized with the sequence of a t(15;17) translocation observed in a t-APL patient 
treated with mitoxantrone for MS, which was also observed to be a strong site of mitoxantrone-
induced cleavage in vitro[99]. 
The proof-of-principle experiments presented in Chapter 4 aimed to determine if OTIs could 
induce cleavage by type II topoisomerases, and whether said cleavage could be constrained by 
the sequence specificity of the employed OTI. Initial results with OTI28 indicated that (when 
hybridized to a complementary oligonucleotide) the OTI could induce higher levels of 
topoisomerase IIα- and IIβ-mediated DNA cleavage compared to free etoposide (Figure 23). 
Further testing suggested that the inclusion of the DEPT on the OTI was chemically necessary 
for its poisoning of type II topoisomerases, the other possibility being that the OTIs acted as DNA 
lesions that enhanced cleavage by the type II topoisomerases. A “precursor” version of OTI28 
(an OTI with a modified nucleotide containing the linker but no DEPT), LIN28 (compound 6, 
Figure 8), did not lead to any enzyme-mediated DNA cleavage (Figure 23). The OTIs inhibited 
DNA religation and stabilized cleavage complexes on a similar timescale as free etoposide 
(Figure 26), results that would not be expected were the OTIs acting like DNA lesions. As lesions 
that act as topoisomerase II poisons act by enhancing the forward rate of cleavage instead of 
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inhibiting religation or stabilizing cleavage complexes[18, 92, 152-159], the effects of the OTIs 
are believed to be mediated by the tethered drug moiety as opposed to a distortion in the double 
helix. These results were supported by the decrease in cleavage enhancement observed when 
an OTI-containing double-stranded oligonucleotide was incubated with a mutant yeast 
topoisomerase II that was resistant to etoposide (Figure 28)[201]. 
To determine whether or not type II topoisomerases could be directed to cleave at specific 
sequences, three new OTIs were generated that varied in the position of the attached DEPT. 
The results observed in Figure 29 indicate that incubation of each OTI with the type II 
topoisomerases resulted in unique cleavage patterns. Two takeaway points can be gleaned from 
these data. First, OTIs can be used to induce DNA cleavage, at least in part, in a predictable 
manner, as strong topoisomerase IIα-mediated DNA cleavage induced by the new OTIs was 
observed two bases away opposite the drug location (Figure 29). Second, sites of cleavage can 
be moved to sequences not normally associated with the actions of free etoposide (Figures 23 
and 29), suggesting that sequences generated by novel translocations in cancer cells could still 
be targeted even though they do not represent previously-observed topoisomerase II cleavage 
sites. 
The key experiments demonstrating the potential of OTIs involved the incubation of 
topoisomerase IIα and IIβ with non-complementary duplexes. No DNA cleavage was observed 
when either enzyme was incubated with a PML top strand or a RARA top strand and a PML-
RARA bottom strand in the presence of free etoposide, nor when either top strand was annealed 
to an OTI that was 50, 30, or 20 nucleotides long (Figure 31). Results demonstrated that the 50-
mer and 30-mer OTIs, but not the 20-mer OTI, were able to increase enzyme-mediated DNA 
cleavage when annealed to complementary PML-RARA oligonucleotides (Figure 30), which 
suggests that OTIs could target their complementary sequence without inducing cleavage of the 
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parental sequences. A 26-mer OTI annealed to a complementary PML-RARA oligonucleotide 
demonstrated similar cleavage as the 30-mer OTI at site 20-21, but markedly reduced cleavage 
at 23-24 (data not shown). As the longer OTIs (50-mer and 30-mer) maintained high levels of 
cleavage at both sites compared to shorter OTIs (20-mer and 26-mer)(Figure 30, data not 
shown), these results suggest that the minimum effective length for the tested OTIs is 
somewhere between 27 and 30 nucleotides long, although the length might depend on the 
specific OTI. 
The final section of Chapter 4 explored the effects of mismatches on the ability of OTIs to 
induce topoisomerase II-mediated DNA cleavage. The reasons for testing DNA duplexes 
containing a mismatch are two-fold. First, although the results with the PML and RARA 
oligonucleotides suggest that OTIs can target translocation sequences, they do not speak to the 
ability of OTIs to target other types of cancer-specific sequences, like SNPs. Second, they can 
afford us mechanistic information as to how the drug-enzyme-DNA ternary complex interacts. 
Type II topoisomerases have a sequence preference for where they cleave[149, 230], and this 
preference changes depending on the presence of different topoisomerase II poisons (Table 
2)[149, 231-235]. OTIs can help us determine if the cleavage site preferences of the enzymes 
change considering that the drug is fixed or “hardwired” into the system. 
Cleavage data on the mismatch oligonucleotides indicates that both type II topoisomerase 
isoforms are capable of inducing DNA cleavage when the substrate includes an OTI (Figures 
33, 34, and 35), but not when the substrate was an unmodified duplex incubated in the presence 
of free etoposide (Figure 32). These data suggest that OTIs are not specific enough for type II 
topoisomerases to discern between a fully complementary sequence and a sequence that 
contains a single mismatch. The implications of these results are that SNPs are not optimal 
targets for OTIs, but imply that OTIs can retain their effectiveness against their target even if 
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new mutations arise at that locus, or if there is genetic variation among a population of cancer 
cells[225]. 
Figure 32 shows that mismatch-containing, non-OTI oligonucleotide duplexes tend to 
decrease cleavage even in the presence of free etoposide, especially when the mismatch is 
located 5’ to a site of cleavage. There were some exceptions, however, which are likely attributed 
to mismatch-induced distortions that are translated down the duplex and that facilitate cleavage 
at other sites[204]. In contrast, data from Figures 33, 34, and 35 suggest that, when OTIs are 
part of the substrate, mismatches 5’ to the cleavage sites tend to maintain lower levels of 
cleavage mediated by both enzymes compared to mismatches 3’ to the cleavage site. Cleavage 
on OTI-containing duplexes was observed even when the cleavage sites had bases at the -1 
position that are not normally preferred either by topoisomerase IIα (A) nor by type II 
topoisomerases in the presence of etoposide (not C or T)[149, 230-235]. Collectively, these data 
suggest that the attachment of the etoposide core onto the OTI is enough to overcome some of 
the physical constraints[121] that normally would prevent a fruitful interaction between the 
enzyme, the drug, and the DNA. 
The experiments described in Chapter 4 provide a promising first look into the use and 
potential of OTIs, but also leave several questions unanswered. OTIs can function in in vitro 
systems where they are annealed to complementary oligonucleotides, but future experiments 
must explore the function of OTIs in situations that are more representative of the cellular 
environment in which their target is double stranded. In vitro experiments suggest that single-
stranded oligonucleotides as short as 24-mers can spontaneously invade the double helix and 
form a D-loop[248]. Results from Figure 30 suggest that OTIs 20 nucleotides long do not induce 
strong levels of cleavage at their target sites, so it is therefore conceivable that the shortest 
effective OTIs could similarly invade the double helix. The strand invasion ability of OTIs could 
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be investigated by incubating them with a modified plasmid bearing a 319-bp segment of PML. 
If no strand invasion is observed, Rad51 could be added into the reactions[249, 250]. Rad51 
has a major role in homologous recombination, as it helps facilitate the invasion of a ssDNA 
strand into a complementary DNA duplex[249, 250]; thus, Rad51 might facilitate the invasion of 
an OTI into the DNA duplex that contains the OTI target sequence. 
Further, experiments exploring the ability of OTIs to interfere with DNA processing systems 
such as transcription and replication are necessary before transitioning into a cellular system. 
To begin, in vitro transcription reactions could be set up to monitor transcription on the PML-
modified plasmid. Monitoring of the products by northern blot analysis would indicate whether a 
OTIs can inhibit the production of the RNA product. Investigations of the effect of OTIs on DNA 
replication could be carried out in Xenopus laevis egg extracts in collaboration with Vanderbilt 
University Department of Biochemistry faculty Dr. James Dewar. His laboratory employs a cell-
free Xenopus egg extract system that promotes sequence non-specific replication of DNA that 
would allow for the use of the PML-modified plasmid[20]. Monitoring the appearance of 
replication products in the presence and absence of an OTI would provide information on 
whether or not the OTIs are capable of interfering with DNA replication. Results of these 
experiments can be compared to those of similar experiments that contain free etoposide but no 
OTI to help discern if the OTIs interfere with replication by acting as topoisomerase II poisons or 
if they interfere by virtue of base pairing with their target. Collectively, the above experiments 
would also inform on whether it is necessary for the DNA duplex to be open for the OTIs to exert 
their function, or whether the OTIs have the capability to invade their target duplexes. 
It is important to note that all of the conducted and proposed experiments thus far are proof 
of concept. OTIs in their current design have two main problems that preclude their use in 
patients or even in cells. First, OTIs have a deoxyribonucleic acid backbone, which makes them 
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immensely susceptible to degradation inside cells[263, 264]. Second, although there have been 
great strides in the development and delivery of RNA and other nucleic acid-based 
therapies[243, 265], there has not been much research into nucleic acid transfection into nuclei 
considering that these technologies tend to target RNAs in the cytosol[243]. 
To address the first issue, there are different modifications that change the structure of the 
backbone that still allow the OTIs to retain sequence specificity for their target, or that could 
delay or prevent their degradation. Peptide nucleic acids (PNA), for example, are non-natural 
analogs of DNA with a N-(2-aminoethyl)glycine backbone that is linked through peptide bonds 
instead of phosphodiester bonds[252]. The nucleobases in PNA retain their spatial arrangement, 
which allows them to base pair with DNA, RNA, and PNA. The peptide backbone of PNA affords 
several advantages over DNA. First, it is not susceptible to enzymatic degradation. Second, it is 
neutral, which reduces the repulsion the DNA backbone has to itself (facilitates packaging for 
drug delivery) and with the opposing strand (enhances hybridization strength)[252]. In fact, the 
hybridization strength of PNA oligomers to complementary PNA and DNA is greater than that of 
DNA to DNA[252]. Thus, PNA-OTIs would likely have a higher affinity for their target DNA 
sequence than the target strand would have to its genomic complement. 
A second possible oligomer structure involves the use of locked nucleic acids (LNA)[243]. 
This type of modification is mainly used in antisense technologies that target RNAs, and is 
characterized by a methylene bridge connecting the 2′-oxygen and the 4′-carbon atoms in 
the furanose ring of ribonucleic acids[243, 266]. Despite being ribonucleotide analogs, LNAs can 
bind to DNA with higher affinity than DNA has to itself[266, 267]. A number of other options are 
available, including nucleic acid analogs with phosphorothioate linkages instead of the canonical 
phosphodiester bonds[243, 265, 268], 2′-O-methoxyethyl-modified oligonucleotides (2′-
MOE)[243, 268], and 2’-O-constrained ethyl-modified (cEt) nucleotides[267]. 
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Research on nucleic acid modifications such as the ones described above has come hand-
in-hand with developments in cell delivery methods[192, 193, 243, 252, 266, 268-270]. Modified 
nucleic acids have been introduced into cells through a variety of mechanisms, including 
encapsulation in nanoparticles[192-194], loading of drugs into hydrogels[195], or through 
receptor-based targeting[194] or antibody-drug conjugation[196] among others. Although most 
of the work to date has focused on drug delivery into cells, there is evidence that some modified 
oligonucleotides, such as LNA, localize to nuclei following transfection[266]. 
The initial experiments with OTIs contained herein demonstrate that they are effective at 
inducing topoisomerase II-mediated DNA cleavage in a sequence-specific manner. 
Developments in oligonucleotide therapies open up the way for further exploration of OTIs 
beyond the current in vitro systems. 
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